amicus therapeutics advancing therapies to treat rare diseases a rare opportunity to join a team that is making a difference in the lives of patients together we can achieve more join the amicus team a rare portfolio of programs development pipeline fabry disease program epidermolysis bullosa eb program pompe disease program preclinical programs previous next july   amicus therapeutics announces closing of underwritten offering of common stock and full exercise of option to purchase additional shares july   amicus therapeutics announces public offering of common stock july   us fda confirms amicus therapeutics may submit new drug application for migalastat for fabry disease read all news » patient voices our programs a rare company patient voices patient advocacy at amicus general disease information patient portraits patient advisory boards resources community support our programs development pipeline fabry disease program epidermolysis bullosa eb program pompe disease program preclinical programs a rare company overview welcome from chairman  ceo leadership amicus belief statement careers our locations contact us patient stories patient advocacy x development pipeline amicus therapeutics programs development pipeline fabry disease program epidermolysis bullosa eb program pompe disease program preclinical programs development pipeline at amicus we are business led and science driven to deliver meaningful benefits to patients we believe that our advanced product pipeline and platform technologies uniquely position us at the forefront of developing therapies to potentially address significant unmet needs for devastating rare and orphan diseases patient stories patient advocacy x investor relations  amicus therapeutics investors investor relations senior management team board of directors corporate governance press releases events  presentations annual reports and proxies sec filings stock performance investor faqs contact us sign up for email alerts investor relations a passionate team with a purpose amicus therapeutics nasdaq fold is a biotechnology company at the forefront of therapies for rare and orphan diseases the company has a robust pipeline of advanced therapies for a broad range of human genetic diseases amicus’ lead programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for fabry disease sd for epidermolysis bullosa eb as well as novel enzyme replacement therapy ert products for fabry disease pompe disease and other lysosomal storage disorders press releases jul   amicus therapeutics announces closing of underwritten offering of common stock and full exercise of option to purchase additional shares jul   amicus therapeutics prices underwritten offering of common stock view all press releases » events  presentations jul   at  am et amicus therapeutics us pathway and upcoming nda submission for migalastat jun   at  am pt goldman sachs th annual global healthcare conference view all events  presentations »   career opportunities amicus therapeutics about us overview welcome from chairman  ceo leadership amicus belief statement careers our locations contact us careers seize an opportunity to make an impact we are currently seeking passionate and qualified candidates in various departments at our various locations working with amicus provides numerous opportunities to be inventive and purposeful and where bold thinking and collaboration are highly valued— and expected amicus is an equal opportunity employer and will judge all applicants based on their qualifications for the job without regard to race color sex religion national origin age disability or any other characteristics protected by applicable federal state or local law click here to read more » please note that we review every submission and will keep all submissions on file for six months unsolicited resumes should not be forwarded to amicus amicus will not be responsible for any fees arising from the use of resumes through this source amicus will only pay a fee to agencies if a formal agreement between amicus and the agency has been established patient stories patient advocacy x leadership team amicus therapeutics about us overview welcome from chairman  ceo leadership amicus belief statement careers our locations contact us leadership a passionate team with a purpose we are driven toward invention and healing committed to delivering meaningful benefits to the rare and orphan disease community our dedicated leadership team is the driving force behind our developments they are constantly inspired by others in the rare disease community and continually aspire to reach new heights senior management team board of directors john f crowley chairman and chief executive officer bradley l campbell president and chief operating officer chip baird chief financial officer daphne quimi senior vice president finance and administration david allsop senior vice president international dipal doshi chief business officer of amicus therapeutics inc and general manager of scioderm inc ellen s rosenberg general counsel and corporate secretary enrique diloné phd rac senior vice president technical operations hung do phd chief science officer jay a barth md chief medical officer jayne c gershkowitz chief patient advocate jeffrey p castelli phd senior vice president program management and portfolio planning kurt jw andrews senior vice president human resources patrik s florencio esq chief compliance officer senior management team john f crowley chairman of the board chief executive officer john f crowley is our chairman and ceo johns involvement with biotechnology stems from the  diagnosis of two of his children with pompe disease—a severe and often fatal neuromuscular disorder in his drive to find a cure for them he left his position at bristolmyers squibb and became an entrepreneur as the cofounder president and ceo of novazyme pharmaceuticals a biotech startup conducting research on a new experimental treatment for pompe disease which he credits as ultimately saving his childrens lives in  novazyme was acquired by genzyme corporation and john continued to play a lead role in the development of a drug for pompe disease as senior vice president genzyme therapeutics john and his family have been profiled on the front page of the wall street journal and are the subjects of a book by pulitzer prizewinning journalist geeta anand the cure how a father raised  millionand bucked the medical establishmentin a quest to save his children the major motion picture extraordinary measures starring brendan fraser and harrison ford is inspired by the crowley family journey john is the author of a personal memoir chasing miracles the crowley family journey of strength hope and joy john is also a commissioned officer in the us navy reserve assigned to the united states special operations command and is a veteran of the global war on terrorism with service in afghanistan he graduated with a bs in foreign service from georgetown university and earned a jd from the university of notre dame law school and an mba from harvard the crowley family was the recipient of the  family exemplar award from the university of notre dame he is also a member of the university council on science  technology at notre dame he is the national chairman of the make a wish foundation of america and is a founding board member of the global genes project john is a henry crown fellow at the aspen institute bradley l campbell president and chief operating officer bradley l campbell is the president and chief operating officer of amicus and brings over  years of experience in the orphan drug industry after joining in  he subsequently took on roles of increasing responsibility throughout the organization in his current capacity mr campbell leads the strategy design and leadership of global commercial operations to support the launch of migalastat a small molecule personalized medicine in development for the treatment of fabry disease he also oversees technical operations global marketing and program management functions prior to amicus mr campbell was with genzyme serving first as product manager for myozyme® for pompe disease and later as business director of their cardiac gene therapy programs he has also worked in sales and marketing for bristolmyers squibb and as a strategy consultant for marakon associates mr campbell is active with various boards and philanthropic organizations he serves as a member of the board of directors of progenics pharmaceuticals a public company developing innovative medicines and other products for targeting and treating cancer he is a member of the bionj board of directors and is amicus’ representative to hinj health care initiative of new jersey board of trustees he is a past president of the national taysachs and allied diseases association board of directors and currently serves on their corporate advisory council bradley received a ba in public policy from duke university and an mba from harvard business school chip baird chief financial officer chip baird joined amicus therapeutics in  as chief financial officer he brings experience in finance operations and strategic planning mr baird spent  years as the cfo of ptc therapeutics also in the rare disease space as chief financial officer of ptc he was responsible for all areas of finance investor and public relations human resources facilities and project management in his roles as cfo mr baird has raised over  billion of capital through a variety of mechanisms including private and public equity convertible and venture debt grant funding and strategic collaborations prior to his corporate roles at amicus and ptc mr baird worked in strategy consulting for lek consulting in their life science group mr baird began his career in commercial banking at first union national bank mr baird received a bs from georgetown universitys edmund a walsh school of foreign service and an mba in finance from the wharton school of the university of pennsylvania daphne quimi senior vice president finance and administration daphne quimi joined amicus in october  and currently serves as senior vice president finance and corporate controller she brings experience in public accounting and financial reporting prior to amicus ms quimi served as director of consolidations and external reporting at bristolmyers squibb she also held roles of increasing responsibility in the finance department at johnson  johnson ms quimi received a bs in accountancy from monmouth university and an mba from the stern school of business of new york university she is a certified public accountant in new jersey and a member of the american institute of certified public accountants and the institute of management accountants david allsop senior vice president international david allsop joined amicus in april  as senior vice president international mr allsop brings international general management and commercial experience in the biopharmaceutical industry between biogen idec and janssencilag with extensive operational and strategic leadership in the areas of neurology autoimmune diseases hemophilia gastroenterology dermatology and renal he has successfully launched three blockbuster therapies internationally as well as many other therapies both nationally and internationally mr allsop has both direct and indirect experience in securing market access and reimbursement in the european union and international markets prior to joining amicus mr allsop was instrumental in building biogen’s international commercial organization over the last  years he most recently served as senior vice president europe and canada with full responsibility for the business and organization in those territories while at biogen he led the successful international launch of several products in the multiple sclerosis franchise including avonex® tysabri® fampyra® tecfidera® and plegridy™ as well as taking responsibility for the hemophilia development organization prior to his tenure at biogen mr allsop spent  years in roles of increasing responsibility at janssencilag working in gastroenterology dermatology and renal including building and running a number of commercial units and taking responsibility for the company’s largest brand in the united kingdom dipal doshi chief business officer of amicus therapeutics inc and general manager of scioderm inc dipal doshi joined amicus in july  and currently serves as chief business officer of amicus and general manager of scioderm inc an amicus company prior to joining amicus mr doshi founded rstreet advisors a healthcare consulting firm through which he advised pharmaceutical biotech and diagnostics companies on business development corporate strategy market and commercial planning activities from  to  mr doshi was the senior vice president and member of the management team at auven therapeutics a mm global private equity and biopharmaceutical development company mr doshi led or participated in the operations and financing of several biotech and pharmaceutical companies and held board observer positions for both spirogen acquired by astrazeneca and adc therapeutics from  to  mr doshi was the head of corporate development for catalent pharma solutions ctlt prior to catalent mr doshi was a member of merrill lynchs investment banking group during his tenure at eli lilly mr doshi was a member of both the strategic marketing team and lilly ventures where he developed and led a portfolio company he was also a sales representative in new york as a consultant for both mercer management consulting oliver wyman and sapient corporation publicis mr doshi advised healthcare consumer and technology companies mr doshi currently serves as member of the board of directors of the children’s health fund a national organization committed to delivering high quality health care to america’s most disadvantaged children mr doshi is a fellow of the second class of the health innovators fellowship and a member of the aspen global leadership network mr doshi received a ba from rutgers university and an mba from the wharton school of the university of pennsylvania ellen s rosenberg general counsel and corporate secretary ellen s rosenberg joined amicus therapeutics in february of  as general counsel and corporate secretary she brings legal experience in the biopharmaceutical and medical device industry including mergers and acquisitions product launches risk management and compliance matters prior to joining amicus she served as senior vice president associate general counsel of shire pharmaceuticals prior to shire ms rosenberg was associate general counsel for the metabolic endocrinology division at emd serono inc the us affiliate of merck kgaa ms rosenberg received a ba from the university of connecticut and a jd from the university of pennsylvania law school enrique diloné phd rac senior vice president technical operations enrique diloné joined amicus in august  and currently serves as senior vice president technical operations he brings experience in drug development prior to joining amicus dr diloné served as executive director of quality and analytics at novadel pharma inc a specialty pharmaceutical company developing oral spray formulations from february  to august  he served as senior directordirector of analytical operations at osieyetech pharmaceuticals from february  to december  he also worked in several pharmaceutical development departments at wyeth and hoffmannla roche dr diloné received a ba in chemistry from new york university and a phd and a ms both in chemistry from seton hall university he graduated from harvard business school’s general management program in  and is certified in us regulatory affairs hung do phd chief science officer hung do joined amicus in december  and currently serves as chief scientific officer dr do brings experience in the field of lysosomal storage diseases lsds and enzyme replacement therapies erts prior to joining amicus dr do was a cofounder and chief scientific officer of callidus biopharma a privatelyheld biologics company that was acquired by amicus prior to founding callidus he headed early discovery research to decipher the mechanism of action for small molecule pharmacological chaperones at amicus he previously helped to demonstrate proofofconcept for erts and served as the project leader for a secondgeneration pompe ert at genzyme dr do also led molecular biology cell culture and purification work and helped develop an in vitro protein modification process for improving drug targeting for protein therapeutics at novazyme which was acquired by genzyme dr do holds a phd in medical biochemistry and genetics from texas am university mentored by professor arthur e johnson and was a postdoctoral fellow in hematologyoncology at emory university dr john s lollar dr do utilizes his focused training in protein synthesis folding  trafficking to develop better targeted therapeutic treatments for genetic diseases jay a barth md chief medical officer jay a barth joined amicus therapeutics in march  as chief medical officer dr barth brings experience in drug development clinical research and medical affairs prior joining amicus dr barth held roles of increasing responsibility at ptc therapeutics inc from  to  he most recently served as ptc’s senior vice president clinical development in this role he led the clinical team and oversaw all global clinical development programs focusing on rare diseases including duchenne muscular dystrophy and cystic fibrosis previously dr barth served as executive director of clinical research at merck as vice president clinical research and medical affairs at altana pharma us inc and as senior director global head of gastroenterology clinical research at eisai medical research inc dr barth received a ba from columbia university and an md from the university of pennsylvania school of medicine he is a member of the american gastroenterological association the american college of gastroenterology and the north american society for pediatric gastroenterology hepatology and nutrition he is also the author of numerous publications in the fields of medicine and clinical research jayne c gershkowitz chief patient advocate jayne c gershkowitz joined amicus in june  and currently serves as chief patient advocate she is a longtime patient advocacy professional with expertise in the rare disease community specifically in the lsd space prior to joining amicus ms gershkowitz served as executive director at the ntsad association where she cofounded the lsd research consortium in partnership with the national institute of neurological disorders and stroke ninds and established the ntsad research initiative her earlier career experience encompasses newspaper journalism corporate and nonprofit marketing communications and social services ms gershkowitz is active in several organizations within the rare disease community as well as the broader biotech arena she is a cofounder and chair of the patient advocacy committee of bionj and vice president of education of the board of directors of the ntsad association she is currently a member of the steering committee of the healthcare institute of new jersey the patient advocacy and access and reimbursement committees of the corporate alliance of the global genes rare project and the policy working group of the national organization for rare disorders corporate council ms gershkowitz earned a degree in journalism from the the newhouse school of public communications at syracuse university and studied business administration at the radcliffe graduate seminars program jeffrey p castelli phd senior vice president program management and portfolio planning jeffrey p castelli joined amicus in july  and currently serves as senior vice president program management and portfolio planning he brings experience in program management business operations alliance management and as a management consultant prior to joining amicus dr castelli was a manager at health advances llc and previously served as a business development analyst at neose pharmaceuticals inc dr castelli received a bs from west chester university and a phd from the university of pennsylvania kurt jw andrews senior vice president human resources kurt jw andrews joined amicus therapeutics in february of  as senior vice president human resources mr andrew brings experience working in leadership roles at biotechnology and technology companies including business and commercial strategy implementation of organizationwide goals and strategies performance management and compensation planning prior to joining amicus mr andrews served as vice president human resources at valeritas inc previously mr andrews was vice president human resources and administration at ptc therapeutics inc mr andrews earned a ba and ma from the university of illinois at urbanachampaign patrik s florencio esq chief compliance officer patrik florencio joined amicus therapeutics in august  as chief compliance officer prior to amicus mr florencio was the chief compliance officer of nps pharmaceuticals inc previously he was the chief compliance officer of sandoz inc where he led both corporate compliance and served as corporate security for almost nine years prior to joining sandoz mr florencio practiced health law at the law firm of ropes  gray in new york city where he counseled pharmaceutical hospital system academic medical center and other healthcare clients on a host of government enforcement compliance and regulatory matters mr florencio graduated with degrees in common law civil law and neuroscience from mcgill university in montreal canada donald j hayden  jr lead independent director glenn p sblendorio executive vice president chief operating officer and chief financial officer ophthotech margaret g mcglynn rph michael g raab chief executive officer and chairman ardelyx robert essner senior advisor the carlyle group ted w love md board of directors global blood therapeutics craig a wheeler president and chief executive officer momenta pharmaceuticals board of directors donald j hayden  jr lead independent director donald j hayden jr has served as a member of our board since march  and as lead independent director since february  mr hayden served as chairman from march  until february  and from september  until march  as interim president and chief executive officer from  to  he held several executive positions with bristolmyers squibb company most recently serving as executive vice president and president americas mr hayden is senior advisor to prospect venture partners a life sciences venture capital firm since  and is a member of the board of directors of insmed incorporated vitae pharmaceuticals regenexbio and otsuka tokyo mr hayden holds a ba from harvard university and an mba from indiana university glenn p sblendorio executive vice president chief operating officer and chief financial officer ophthotech glenn p sblendorio has served as a member of our board since june  since april   mr sblendorio has served as executive vice president chief operating officer and chief financial officer of ophthotech corporation and was a member of the board of directors of ophthotech until march   prior to opthotech mr sblendorio was president and chief financial officer of the medicines company from march  through march  and was a member of the board of directors of the medicines company from july  through december   before joining the medicines company mr sblendorio was executive vice president and chief financial officer of eyetech pharmaceuticals inc from february  until it was acquired by osi pharmaceuticals inc in november  mr sblendorio also serves as a member of the boards of directors of intercept pharmaceuticals and nulens ltd a privately held company mr sblendorio received his bba from pace university and his mba from fairleigh dickinson university margaret g mcglynn rph margaret g mcglynn has served as a member of our board since october  ms mcglynn has served as ceo and president of the international aids vaccine initiative since july  she previously served as president vaccines and infectious diseases of merck  co inc from  until her retirement in  ms mcglynn joined merck in  and served in a variety of marketing sales and managed care roles currently ms mcglynn serves as a member of the boards of directors of air products and chemicals inc and vertex pharmaceuticals inc she is also a member of the national industrial advisory committee at the university at buffalo school of pharmacy and pharmaceutical sciences ms mcglynn holds a bs in pharmacy and a mba in marketing from the state university of new york at buffalo michael g raab chief executive officer and chairman ardelyx michael g raab has served as a member of our board of directors since  mr raab has served as president and chief executive officer of ardelyx inc since march  mr raab previously served as a partner of new enterprise associates from june  until december  from  to  he was a senior vice president therapeutics and general manager renagel® at genzyme corporation mr raab currently serves as a member of the board of directors of ardelyx inc mr raab holds a ba from depauw university robert essner senior advisor the carlyle group robert essner has served as a member of the board since june  mr essner is senior advisor to the global healthcare group at the carlyle group a global private equity firm mr essner retired as chairman and chief executive officer of wyeth now part of pfizer in  during his year career in the pharmaceutical industry he held several prominent leadership positions including chairman of the pharmaceutical research and manufacturers association prior to wyeth mr essner spent more than a decade in various management positions at sandoz pharmaceuticals corporation and as president of sandoz consumer healthcare group mr essner is currently a director at massmutual financial group chairman mr essner is also an executiveinresidence and adjunct professor at columbia business school where he teaches courses in healthcare management he received a bachelors degree from miami university and a masters degree from the university of chicago ted w love md board of directors global blood therapeutics ted w love md has served as a member of the board since june  from february  to august  dr love served as executive vice president and head of research and development of onyx pharmaceuticals from  to  dr love was the president chief executive officer and chairman of the board of directors of nuvelo before joining nuvelo in  he served as senior vice president of development at theravance inc prior to that dr love spent six years at genentech inc in a number of senior management positions in medical affairs and product development as vice president of product development and regulatory affairs at genentech dr love oversaw all drugs in development including herceptin rituxan and tnkase he also served as chairman of genentechs product development committee in addition to amicus dr love currently serves on the board of directors of oncothyreon and global blood ceo dr love holds a ba in molecular biology from haverford college and an md from yale medical school craig a wheeler president and chief executive officer momenta pharmaceuticals craig a wheeler has served as a member of our board since june  he is currently president and chief executive officer of momenta pharmaceuticals inc where he also serves on the board of directors mr wheeler led momenta through the launch of its first complex drug products including the first generic versions of lovenox® and oncedaily copaxone® prior to momenta craig worked at chiron corporation as president chiron biopharmaceuticals now novartis vaccines map diagnostics prior to joining chiron craig was a senior member of the boston consulting groups health care practice mr wheeler also worked for mercks msdrl research unit where he served as a senior engineer in process development and at hybritech as a financial analyst mr wheeler previously served for nine years as the chairman of the board of avanir pharmaceuticals where he helped oversee the transition of the company from a researchbased platform to a fully integrated cns pharmaceutical company until  when it was acquired by otsuka pharmaceuticals for  billion he also served as gpha’s chairman of the board of directors from  to february  he holds a bs and an ms degree in chemical engineering from cornell university and an mba from the wharton school of the university of pennsylvania patient stories patient advocacy x global locations and contacts amicus therapeutics about us overview welcome from chairman  ceo leadership amicus belief statement careers our locations contact us global locations international headquarters amicus therapeutics uk ltd phoenix house oxford road tatling end gerrards cross buckinghamshire sl ap united kingdom      infoamicusrxcouk  wwwamicusrxcouk corporate headquarters amicus therapeutics inc  cedar brook drive cranbury nj  usa    infoamicusrxcom germany amicus therapeutics gmbh willybrandtplatz   münchen germany        infoamicusrxde  wwwamicusrxde italy amicus therapeutics srl via giovanni boccaccio  ° floor  milano       infoamicusrxit  wwwamicusrxit france amicus therapeutics sas maison de la défense  place de la défense  paris la défense cedex france         infoamicusrxfr  wwwamicusrxfr netherlands amicus therapeutics bv science park  xh amsterdam the netherlands       infoamicusrxnl  wwwamicusrxnl spain amicus therapeutics sp calle orense nº  ª planta  madrid  spain        infoamicusrxes  wwwamicusrxes patient stories patient advocacy x company profile amicus therapeutics about us overview welcome from chairman  ceo leadership amicus belief statement careers our locations contact us company profile we are passionate about what we do amicus therapeutics inc nasdaqfold is a global biotechnology company at the forefront of advanced therapies to treat a range of devastating rare and orphan diseases we have a robust development pipeline of treatments for a range of human genetic diseases our lead product candidate migalastat is a personalized medicine in latestage development to treat individuals with fabry disease on the basis of their genetic diagnosis sd a product candidate in latestage development is a potential firsttomarket therapy for the rare genetic connective tissue disorder epidermolysis bullosa eb we are leveraging our biologics and chaperoneadvanced replacement therapy chart™ platform technologies to develop novel enzyme replacement therapy ert products for fabry disease pompe disease and other lysosomal storage disorders lsds our lead biologics program is atbat a uniquely engineered pompe disease ert that will be administered in combination with a pharmacological chaperone patient stories patient advocacy x amicus therapeutics inc  product pipeline review    compare about us  contact us home research category publisher list custom research cart compare research category user guide policies contact us about us site map home  market research report  pharmaceutical  pharmaceutical companies  pharma info market research report amicus therapeutics inc  product pipeline review   published by global markets direct product code  published july   content info  pages price usd  pdf by email single user license usd  pdf by email site license usd  pdf by email global license amicus therapeutics inc  product pipeline review   published july   content info  pages description summary global markets directs amicus therapeutics inc  product pipeline review   provides an overview of the amicus therapeutics incs pharmaceutical research and development focus this report provides comprehensive information on the current therapeutic developmental pipeline of amicus therapeutics incs complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projects global markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets directs team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass products note certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease scope the report provides brief overview of amicus therapeutics inc including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of amicus therapeutics incs human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement latest news and deals relating to the amicus therapeutics incs pipeline products reasons to buy evaluate amicus therapeutics incs strategic position with total access to detailed information on its product pipeline assess the growth potential of amicus therapeutics inc in its therapy areas of focus identify new drug targets and therapeutic classes in the amicus therapeutics incs rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of amicus therapeutics inc and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of amicus therapeutics inc develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of amicus therapeutics inc and identify potential opportunities in those areas avoid intellectual property rights related issues table of contents product code gmdhccdbtable of contents table of contents list of tables list of figures amicus therapeutics inc snapshot amicus therapeutics inc overview key information key facts amicus therapeutics inc  research and development overview key therapeutic areas amicus therapeutics inc  pipeline review pipeline products by stage of development pipeline products  monotherapy pipeline products  combination treatment modalities pipeline products  partnered products partnered productscombination treatment modalities amicus therapeutics inc  pipeline products glance amicus therapeutics inc  late stage pipeline products preregistration productscombination treatment modalities phase iii productscombination treatment modalities amicus therapeutics inc  clinical stage pipeline products phase ii productscombination treatment modalities amicus therapeutics inc  early stage pipeline products preclinical productscombination treatment modalities amicus therapeutics inc  drug profiles migalastat hydrochloride product description mechanism of action rd progress migalastat hydrochloride  agalsidase alfa product description mechanism of action rd progress duvoglustat hydrochloride  alglucosidase alfa product description mechanism of action rd progress duvoglustat hydrochloride  atb product description mechanism of action rd progress afegostat tartrate product description mechanism of action rd progress afegostat tartrate  ert product description mechanism of action rd progress at product description mechanism of action rd progress atb product description mechanism of action rd progress chaperoneert combinations product description mechanism of action rd progress laronidase  chaperone product description mechanism of action rd progress migalastat hydrochloride  enzyme replacement therapy biobetter product description mechanism of action rd progress recombinant enzyme for lysosomal storage disorder product description mechanism of action rd progress small molecule for neurodegenerative diseases product description mechanism of action rd progress amicus therapeutics inc  pipeline analysis amicus therapeutics inc  pipeline products by target amicus therapeutics inc  pipeline products by route of administration amicus therapeutics inc  pipeline products by molecule type amicus therapeutics inc  pipeline products by mechanism of action amicus therapeutics inc  recent pipeline updates amicus therapeutics inc  dormant projects amicus therapeutics inc  company statement amicus therapeutics inc  locations and subsidiaries head office other locations  subsidiaries appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tables amicus therapeutics inc key information amicus therapeutics inc key facts amicus therapeutics inc  pipeline by indication  amicus therapeutics inc  pipeline by stage of development  amicus therapeutics inc  monotherapy products in pipeline  amicus therapeutics inc  combination treatment modalities in pipeline  amicus therapeutics inc  partnered products in pipeline  amicus therapeutics inc  partnered products combination treatment modalities  amicus therapeutics inc  preregistration  amicus therapeutics inc  phase iii  amicus therapeutics inc  phase ii  amicus therapeutics inc  preclinical  amicus therapeutics inc  pipeline by target  amicus therapeutics inc  pipeline by route of administration  amicus therapeutics inc  pipeline by molecule type  amicus therapeutics inc  pipeline products by mechanism of action  amicus therapeutics inc  recent pipeline updates  amicus therapeutics inc  dormant developmental projects amicus therapeutics inc subsidiaries list of figures amicus therapeutics inc  pipeline by top  indication  amicus therapeutics inc  pipeline by stage of development  amicus therapeutics inc  monotherapy products in pipeline  amicus therapeutics inc  combination treatment modalities in pipeline  amicus therapeutics inc  pipeline by top  target  amicus therapeutics inc  pipeline by top  route of administration  amicus therapeutics inc  pipeline by top  molecule type  amicus therapeutics inc  pipeline products by top  mechanism of action  phone intl  tollfreeus  europe  asia  new for   gii now purchases any market research reports from any publishers for you with noextra cost contact us for more details faq delivery time user license payment options compare multiple reports about contact user guide policies site map  copyright  global information inc all rights reserved amicus therapeutics inc nasdaqfold sees volume pop in session home » electronics amicus therapeutics inc nasdaqfold sees volume pop in session  july    author pamela mathis its down  from  in q for the quarter shares have been noted at   million shares or  more from  million shares in q were reportedbrown advisory marylandbased fund reported  shares for the next fiscal year analysts anticipate that the company will report sales of  million per share with estimates ranging from  million to  millionsupport is likely to come between  a share to  a share level pacad inv accumulated  or  shares paloma prtnrs mngmt com reported  shares wells fargo mn holds  or  shares in its portfolio d e shaw inc has invested  in amicus therapeutics inc nasdaqfold for  shares nationwide fund advisors invested in  shareswall street brokerages expect amicus therapeutics inc nasdaqfold kcg accumulated  or  shares us bancshares de holds  or  shares principal financial group inc boosted its stake in shares of amicus therapeutics by  in the first quarteramicus therapeutics nasdaqfold last released its quarterly earnings data on tuesday may th the mf rank of amicus therapeutics inc nasdaqfold for  shares aperio group llc now owns  shares of the biopharmaceutical companys stock valued at  after buying an additional  shares during the period do hung had sold  shares worth  supreme court oks expanded list of relatives exempt from travel ban trumps administration initially interpreted this to mean a parent spouse sibling son daughter soninlaw or daughterinlaw however they barred grandparents grandchildren aunts uncles nieces nephews cousins brothersinlaw and sistersinlaw recent session action on shares of amicus therapeutics inc also insider jay barth sold  shares of the firms stock in a transaction dated monday june th nasdaqfold opened at  on wednesday to measure pricevariation we found folds volatility during a week at  and during a month it has been found around  the year high was reported on jul  by barchartcom they now have a dollars  price target on the stock the stock has lost  reaching at  after hovering between  and  during such notable technical setup fundamental investors usually stay away and are careful shorting or selling the stock fold has the trading volume of  million shares with the average trading volume of  shares it has underperformed by  the sp parametric associates ltd holds  of its portfolio in amicus therapeutics inc nasdaqfold by some  shares  decreased positions by  and  held positions by  after having  eps previously inuvo incs analysts see  eps growth this company shares are  off its target price of  and the current market capitalization stands at b therefore  are positive over the trailing year the stock is outperforming the sp  by  and its gotten there by action that has been more volatile on a daytoday basis than most other stocks on the exchange the price range of amicus therapeutics inc finally chardan capital reiterated a buy rating and set a  price objective on shares of amicus therapeutics in a report on thursday june st the third largest holder is blackrock inc which now holds  million worth of this stock and that ownership represents almost  of its market capitalization the rating was maintained by cowen  co on sunday june  with buy the firm has outperform rating by robert w baird given on tuesday january  on tuesday march  the stock rating was upgraded by janney capital to buy as per wednesday may  the company rating was initiated by bank of americafolds fiscal year ends dec   and the most recent quarter started on mar   the fcf growth of amicus therapeutics inc the stock has a day moving average of  and a day moving average of  as traders we are more interested to take part in strong moves and dont join moves that show weakness  or we may even watch for an entry in the opposite direction of a weak movefold has been the topic of a number of recent analyst reportsthe qi value of amicus therapeutics incis  the company has market cap of  billion the firm is engaged in the discovery development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases it now has negative earnings its lead product migalastat hcl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy ert for fabry diseasereceive news  ratings via email  enter your email address below to receive a concise daily summary of the latest news and analysts ratings with our free daily email newsletter recommended institutional investors are buying quaker chemical corp nysekwr with  avg volume  days are for quaker chemical corporation nysekwrs short sellers to cover kwrs short positions hsbc holding public ltd company reported  shares nysevz stake by  shares and now owns  shares  july  police suspend investigation involving cowboys rb ezekiel elliott cite lack of witnesses while nothing has resulted in any type of discipline yet the league is looking at the accumulative nature of these incidents columbus ohio prosecutors did not think there was enough evidence to bring charges and dropped the case  july  ltd boosts stake in advance auto parts inc aap buss brad w bought  worth of advance auto parts inc nyseaap has risen  since july   and is uptrending the institutional investor owned  shares of the companys stock after buying an additional  shares during the period  july  exxon mobil fined m for violating russian federation sanctions it also determined that exxon had not voluntarily disclosed the violations which it said was an egregious case president obama signed an executive order establishing sanctions on russian federation on march    july  kylian mbappe illegally approached by big european clubs say monaco monaco has ordered leading european clubs to stop making unauthorized approaches to prolific teen forward kylian mbappe mbappé has a contract until  and no club can speak to him without monacos permission  amazoncom inc amzn receives buy rating from deutsche bank ag the massachusettsbased trillium asset management ltd co has invested  in enernoc inc nasdaq amzn  for  shares as per thursday april  the company rating was maintained by jp morgan nasdaq amzn  shares were sold by ryder thomas o  july  uks liberal democrats make vince cable party leader prior to that hed earned a reputation as an economic forecaster when he warned of signs of the coming global financial crisis in the united kingdom economy  july  hyperloop approved between nyc and dc says elon musk musk didnt clarify who exactly gave the company verbal approval and whether or not it came from different state representatives its unclear whether musk would look to partner with an outside hyperloop development team or step up inhouse development envestnet asset management inc reduces position in triumph group inc tgi the aerospace company reported  earnings per share for the quarter topping the consensus estimate of  by  also the number of funds holding triumph group inc in their top  positions decreased from  to  for a decrease of   july  prisoner escapes after being handcuffed in staten island calo was on parole for a burglary he served time in state prison in fishkill and was conditionally released in august  the nypd says all calls and texts are strictly confidential  july  mariners acquire rhp david phelps from marlins in return for prospects the mariners may have just made a move that keeps felix hernandez james paxton and other starters from getting worn out the  seattle mariners and general manager jerry dipoto are certainly not throwing in the towel just yet  july  las vegas party the ideal open warmup for koepka however conditions eased somewhat as the day wore on allowing twotime major victor spieth and koepka last months us ive been on good ends of the draw bad ends of the draw popular sherwinwilliams co shw shares sink on profit miss weak outlook on  announced a quarterly dividend of  with an ex dividend date of  which will be payable on  finally ardevora asset management llp raised its position in sherwinwilliams company the by  in the second quarter detroit tigers chicago cubs discussing trade for alex avila report says its interesting when looking at the kansas city royals roster because their biggest needs are mostly at the pitching position eric hosmer homered his th on a  warwick saupold pitch to lead off the kansas city eighth cutting the deficit to  general electric company ge stake lowered by west coast financial llc it is negative as  investors sold ge shares while  reduced holdings  funds opened positions while  raised stakes therefore  are positive   general electric company had its  rating reiterated by analysts at citigroup cavs in serious talks with derrick rose rose played in  games last season with the new york knicks  scoring  points per game shooting  percent from the floor the free agent point guard is in serious talks with the cleveland cavaliers on a oneyear contract espn reported thursday exxon mobil corporation nysexom shares sold by adams asset advisors llc gyroscope capital management group llc increased its stake in shares of exxon mobil corporation by  in the fourth quarter since march   it had  insider purchases and  insider sale for  activity nyseibm on tuesday may  ap analysis trump putin met again in germany independent voter jack murray a yearold barber in bethlehem cast his first vote in a presidential election for mr people executive editor sara nathan says the magazines story looks at the strategy behind this familys power trip inverness womans apollo  moon rocks put up for auction the bycentimetre bag from the apollo  mission was misidentified and sold at an online government auction in  it plans to take up the issue next month at the starship congress  in california tn mlas salary hike row jd u appears divided the tamil nadu state government of india says it will send  pilgrims to muktinath of nepal every year under a subsidy scheme the protesting farmers at jantar mantar said that they were very unhappy with the salary hike of tamil nadu mlas trump jr to face us senate committee next week putin and trump did not discuss the issue of washingtons support for rebels in syria according to peskov trumps chat part of the rationale is the flurry of bilateral contacts that happen the official said are insiders selling their positions in lhc group inc nasdaqlhcg parametric portfolio assocs limited liability company holds  of its portfolio in lhc group  inc nasdaqlhcg for  shares lhc group nasdaqlhcg has insider ownership of  and institutional ownership of  nasdaqlhcg for  shares latest abercrombie  fitch nyseanf getting somewhat negative media coverage analysis shows timberwolves working on andrew wiggins extension cf industries holdings inc nysecf reviewed by analysts trump jr manafort to testify on russia ties before senate judiciary committee game of thrones creators take on history with alternate timeline series confederate google expeditions app featuring virtual tours now open to all miway probing racist email bhp expands us shale operation despite low oil price us declines to no  in global retirement security ranking blackberry encryption approved for government use tendencies eldorado gold corp usa ego analysts see  eps braves beat la after wood unravels spieth in front after second round at the open making dunkirk was an enormous responsibility says nolan us open  hs prannoy parupalli kashyap look to book spot in finals technical reports on biotech equities  amicus therapeutics pulmatrix amgen and bioverativ technical reports on biotech equities  amicus therapeutics pulmatrix amgen and bioverativ news provided by chelmsford park sa jul    et share this article new york july   prnewswire  if you want a stock review on fold pulm amgn or bivv then come over to httpdailystocktrackercomregister and sign up for your free customized report today dailystocktrackercom is currently evaluating amicus therapeutics inc nasdaq fold pulmatrix inc nasdaq pulm amgen inc nasdaq amgn and bioverativ inc nasdaq bivv these stocks operate in the biotech space which is a notoriously risky business as per investopedia many biotech products do not produce the desired results consistently while others fail to gain acceptance in the marketplace of course when a biotech product succeeds investors can make a lot of money learn more about these stocks by downloading their comprehensive and free reports from dailystocktrackercom members area at httpdailystocktrackercomregister amicus therapeutics  cranbury new jersey headquartered amicus therapeutics incs shares finished fridays session  higher at  a total volume of  million shares was traded which was above their three months average volume of  million shares the stock has surged  in the last month  over the previous three months and  on an ytd basis the companys shares are trading above their day and day moving averages by  and  respectively moreover shares of amicus therapeutics which engages in the discovery development and commercialization of medicines for various rare and orphan diseases have a relative strength index rsi of  on july th  amicus therapeutics announced that it has commenced a million underwritten public offering of its common stock the company expects to grant the underwriters a day option to purchase up to an additional  of the shares of common stock offered in the public offering the offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed or as to the final size or terms of the offering fold complete research report is just a click away at httpdailystocktrackercomregistrationsymbolfold pulmatrix  shares in lexington massachusetts headquartered pulmatrix inc ended the day flat at  with a total trading volume of  shares the stock has skyrocketed  since the start of this year the companys shares are trading  above their day moving average moreover shares of pulmatrix which engages in developing inhaled therapies to address serious pulmonary diseases using its inhaled small particles easily respirable and emitted technology have an rsi of  the complimentary report on pulm can be downloaded at httpdailystocktrackercomregistrationsymbolpulm amgen  thousand oaks california headquartered amgen incs stock rose  closing the session at  a total volume of  million shares was traded the companys shares have gained  in the last one month  in the previous three months and  on an ytd basis the stock is trading  above its day moving average and  above its day moving average additionally shares of amgen which discovers develops manufactures and delivers human therapeutics worldwide have an rsi of  on july th  research firm jefferies resumed its buy rating on the companys stock on july th  amgen and allergan plc announced that they will discuss data supporting the abp  biologics license application with the oncologic drugs advisory committee of the us food and drug administration during the meeting the former will present a comprehensive data package including the analytical pharmacokinetic and clinical data which will demonstrate that abp  and avastin® bevacizumab are highly similar with no clinically meaningful differences in terms of the efficacy safety and immunogenicity between the products sign up for your complimentary research report on amgn at httpdailystocktrackercomregistrationsymbolamgn bioverativ  on friday shares in waltham massachusetts headquartered bioverativ inc finished the session  lower at  a total volume of  million shares was traded the stock has gained  in the last month  over the previous three months and  on an ytd basis the companys shares are trading above their day and day moving averages by  and  respectively moreover shares of bioverativ which focuses on the research discovery development and commercialization of therapies for the treatment of hemophilia and other blood disorders in the us and japan have an rsi of  on june th  research firm jefferies resumed its buy rating on the companys stock on july th  bioverativ announced that it will report its financial results for q ending june th  on august nd  after the market closes the press release will be available under the investor relations section of the companys website additionally the company will host a live webcast on august rd  at  am edt to discuss the financial results get free access to your research report on bivv at httpdailystocktrackercomregistrationsymbolbivv  daily stock tracker  daily stock tracker dst produces regular sponsored and nonsponsored reports articles stock market blogs and popular investment newsletters covering equities listed on nyse and nasdaq and microcap stocks dst has two distinct and independent departments one department produces nonsponsored analyst certified content generally in the form of press releases articles and reports covering equities listed on nyse and nasdaq and the other produces sponsored content in most cases not reviewed by a registered analyst which typically consists of compensated investment newsletters articles and reports covering listed stocks and microcaps such sponsored content is outside the scope of procedures detailed below  dst has not been compensated directly or indirectly for producing or publishing this document  press release procedures the nonsponsored content contained herein has been prepared by a writer the author and is fact checked and reviewed by a third party research service company the reviewer represented by a credentialed financial analyst for further information on analyst credentials please email contactdailystocktrackercom rohit tuli a cfa® charterholder the sponsor provides necessary guidance in preparing the document templates the reviewer has reviewed and revised the content as necessary based on publicly available information which is believed to be reliable content is researched written and reviewed on a reasonableeffort basis the reviewer has not performed any independent investigations or forensic audits to validate the information herein the reviewer has only independently reviewed the information provided by the author according to the procedures outlined by dst dst is not entitled to veto or interfere in the application of such procedures by the thirdparty research service company to the articles documents or reports as the case may be unless otherwise noted any content outside of this document has no association with the author or the reviewer in any way   no warranty  dst the author and the reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error mistake or shortcoming no liability is accepted whatsoever for any direct indirect or consequential loss arising from the use of this document dst the author and the reviewer expressly disclaim any fiduciary responsibility or liability for any consequences financial or otherwise arising from any reliance placed on the information in this document additionally dst the author and the reviewer do not  guarantee the accuracy timeliness completeness or correct sequencing of the information or  warrant any results from use of the information the included information is subject to change without notice  not an offering  this document is not intended as an offering recommendation or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only please read all associated disclosures and disclaimers in full before investing neither dst nor any party affiliated with us is a registered investment adviser or brokerdealer with any agency or in any jurisdiction whatsoever to download our reports read our disclosures or for more information visit httpdailystocktrackercomdisclaimer contact for any questions inquiries or comments reach out to us directly if youre a company we are covering and wish to no longer feature on our coverage list contact us via email andor phone between  edt to  edt from monday to friday at email contactdailystocktrackercom phone number  office address  rivonia boulevard rivonia south africa cfa® and chartered financial analyst® are registered trademarks owned by cfa institute source chelmsford park sa jul    et preview initiating research reports on application software equities  sphere d cadence design systems innoviva and shopify jul    et preview technical snapshots for these banking stocks  zions bancorp umpqua banc of california and western alliance bancorp my news release contains wide tables view fullscreen also from this source jul    et technical insights on textile stocks  lululemon athletica jul    et stock performance review on insurance industry  allied world explore more news releases in similar topics biotechnology health care  hospitals medical pharmaceuticals investments opinions you just read technical reports on biotech equities  amicus therapeutics pulmatrix amgen and bioverativ news provided by chelmsford park sa jul    et share this article looking to send a news release with pr newswire take advantage of the worlds leading distribution platform sign up to get started request more information have an account log in search searching for your content advanced search amicus therapeutics inc fold has a market value of  billion sunday  july  about us contact info advertising latest news schlumberger limited slb position lowered by capital one national association ubiquiti networks inc ubnt receives  average price target from analysts the daily show says goodbye to sean spicer with in memoriam tribute puerto rico votes to become st state of america main » amicus therapeutics inc fold has a market value of  billion amicus therapeutics inc fold has a market value of  billion  july  fold has the trading volume of  million shares with the average trading volume of  sharestotal cash per share on the most recent quarter is amicus therapeutics inc is a biotechnology company the stock declined  or  reaching  on the news the average volume for csx corporation nasdaqcsx has been  million shares per day over the past  daysfurthermore amicus therapeutics inc it has underperformed by  the sp following the completion of the sale the insider now directly owns  shares of the companys stock valued at  the stock has advanced  to a low over the previous  months and showed declining move  to a high over the same period truecar inc call now has b valuation about m shares traded it has outperformed by  the sp nasdaqmchp or  shares it also reduced china biologic products nasdaqcbpo stake by  shares and now owns  shares ignyta nasdaqrxdx was reduced too starbucks is giving out free iced teas heres how to get them starbucks is hosting a tea party on friday and passing out free samples of its teavana shaken ice tea infusions all three of these bevys are made with housesteeped tea and no artificial flavours or sweeteners amicus therapeutics nasdaqfold has grabbed attention from the analysts when it saw a value increase of  or  points in the last trading session to close at  amicus therapeutics had  analyst reports since august   according to sratingsintel they now have a  price target on the stock up previously from why amicus therapeutics inc fold stock is considered to be overbought cowen  co maintained the stock with buy rating in tuesday september  report according to zacks amicus therapeutics is a biopharmaceutical company developing novel oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases the company was maintained on monday august  by leerink swann nasdaqfold has buy rating given on tuesday july  by cowen  co csx stock price climbed  over the past year yielding a positive weighted alpha of  percent the rating was maintained by cowen  co with buy on sunday june  amicus therapeutics nasdaqfolds price to free cash flow for trailing twelve months is   amicus therapeutics had its outperform rating reaffirmed by analysts at robert w baird csx has a week performance of   amicus therapeutics was upgraded by analysts at valuengine from a strong sell rating to a sell rating nasdaqfold was sold by barth jay campbell bradley l sold  shares worth  amicus therapeutics nasdaqfold has a market cap of  billion and the number of outstanding shares have been calculated  million fold opened at  on thursday palo alto networks inc nysepanw reviewed by analysts on november  bernstein left the company rating at overweight and lowered the price expectation to  from  shares of sonus networks nasdaq sons gained  in june  according to data from sp global market intelligence  investors sentiment decreased to  in q  its down  from  in qseveral analysts have commented on fold shares the stock rose  or  reaching  per share first citizens bank  trust  tru holds  in microchip technology inc nasdaqfold weiss multi owns  shares or  of their us portfolio fold is its earnings per share or eps nasdaqfold cubist systematic strategies ltd liability co owns  shares or  of their us portfolio  were accumulated by schwab charles inv management total debtequity is  and the book value per share is  blackrock gru accumulated  shares if the stock price is unchanged its weighted alpha will be smaller bancshares of america corporation de stated it has  of its portfolio in amicus therapeutics inc ubs asset mngmt americas accumulated  shares or  of the stock citigroup incorporated invested in  or  sharesj goldman  company lp increased pinnacle entmt inc new stake by  shares to  valued at m in q amarin corp plc nasdaqamrn was raised too the shares price has positioned  up over the past quarter while it has directed  toward a rising position throughout past six months therefore  are positive stocks weekly performance expressed up trend of  washington com reported  shares the firm has neutral rating by jp morgan given on friday july  the firm has buy rating by zacks given on tuesday august investors sentiment decreased to  in  q its down  from  in q  funds opened positions while  raised stakes arizona state retirement sys invested in  or  shares  were reported by bennicas and inc moreover northern has  invested in truecar inc nasdaqtrue for  shares quantitative invest lc accumulated  shares  are held by commercial bank of montreal can grand jury indicts man for murder of bowie state university student police say collins was just visiting the campus and was waiting at a bus stop for a ride home when he was attacked police have said it was random and the two young men did not know each other the total number of shares percentage held by insiders is about  while the number of shares  held by institutions is  boston private wealth limited liability co massachusettsbased fund reported  shares zurcher kantonalbank zurich cantonalbank holds  or  shares davidson kempner management limited partnership new yorkbased fund reported  shares columbus circle investors holds  shares or  of its portfolio thrivent financial for lutherans holds  or  shares oakmont owns  shares related articles havaianas flipflop brand sold for £m as scandalhit owners sell stake united states producer prices unexpectedly rise in june wimbledon keeps forcing players to change their underwear seagate technology plc nasdaqstx institutional investor sentiment trend atf agents involved in shooting airbnb host who canceled reservation using racist comment must pay  donotpay expands to help lowincome people tackle workplace rights the community health systems inc nysecyh bonds rise  during trading watch tom hardy and harry styles lead cast on the red carpet banco bradesco sa nysebbd stock rating lowered by valuengine share  previous endurance international group holdings inc next ed names sad leader in rs  crore drug case case advertising more news latino medical enrollees sue california over reimbursement rates you can now book appointments at spas and salons on google concur to allow travel agents to book airbnb hurricanes close to selling for m trio of south african lions shot dead after reserve escape inphi corporation iphi analysts see  eps factors to note before buying cara therapeutics inc cara eus barnier says clock is ticking not whistling on brexit endurance international group holdings inc emmys stranger things barb actress scores surprise nomination trump to travel to paris amid controversy at home ed names sad leader in rs  crore drug case case the bank of nova scotia takes position in nordstrom inc jwn inec to maintain status quo on dinos recall the oasis petroleums nyseoas buy rating reiterated at jefferies group llc copyright   healthcaremenu  all rights reserved fold stock price  amicus therapeutics inc stock quote us nasdaq  marketwatch sections watchlist signup • login search bulletin us europe asia fx rates futures range d d m m m y y djia f    sp f    nasdaq f    gold    silver    crude oil    sp  movers ctas  cof  etfc  syf  hp  isrg  hban  chk  latest newsall times eastern a your next online order could be picked out by a robot a  costly mistakes people make when buying cars a what’s a cameo – like ed sheeran on game of thrones – actually worth  updated trump says he has ‘complete power to pardon’  lawmakers reach deal on russia sanctions bill reports  alphabet earnings a  billion hit for google potential youtube results for investors  updated you can date someone who looks just like donald trump with this new online service  updated want to buy happiness splurge on these  things  this is what people really buy when they emotionally overspend hint it’s not designer clothes  updated john mccain is a war hero — but think twice before saying he’s ‘battling’ cancer to be replaced home investing quotes stocks united states fold overview compare quotes stock screener earnings calendar sectors nasdaq fold us nasdaq join td ameritrade find a broker amicus therapeutics inc watchlist createfoldalert after hours last updated jul    pm edt delayed quote     after hours volume k close chg chg     advanced charting d d m m m ytd y y all   vol advanced charting  vs avg volume m  day avg  m open  close   day lowhigh  day range   week lowhigh  your watchlist customize marketwatch have watchlists log in to see them here or sign up to get started create account … or log in symbol last chg chg  no items in watchlist there are currently no items in this watchlist add ticker to watchlist go to your watchlist no saved watchlists create a list of the investments you want to track create watchlist …or try this starter list uh oh something went wrong while loading watchlist go to watchlist recently viewed tickers no recent tickers visit a quote page and your recently viewed tickers will be displayed here search tickers overview profile news charts financials historical quotes analyst estimates options sec filings insiders key data open  day range     week range    market cap b shares outstanding m public float m beta  rev per employee k pe ratio na eps  yield na dividend na exdividend date na short interest m   of float shorted  average volume m performance  day   month   month  ytd   year  recent news marketwatch other dow jones nasdaq extends win streak as stocks digest latest political drama jul   at  pm et by victor reklaitis amicus therapeuticss stock soars on heavy volume after fda clears nda submission for fabry disease treatment shares of amicus therapeutics inc shot up  toward a month high in active premarket trade tuesday after the biotechnology company said the food and drug administration cleared the company to submit a new drug application for its fabry disease treatment volume approached  shares about  minutes before the open making the stock the most actively traded in the premarket session the company said it plans to submit an nda for oral precision medicine migalastat in the fourth quarter of  we are moving ahead expeditiously with our nda submission and accelerating the us pathway for migalastat said chief executive john crowley today is a seminal moment in the development of migalastat and a testament to the dedication and perseverance of the patients physicians and employees who have worked so hard on the development of this precision medicine the stock had doubled year to date through monday while the ishares nasdaq biotechnology etf has climbed  and the sp  has gained  jul   at  am et by tomi kilgore amicus therapeutics stock soars  premarket after fda oks nda submission for fabry disease treatment amicus therapeutics stock soars  premarket after fda oks nda submission for fabry disease treatment jul   at  am et by tomi kilgore charting the technical overhang amid an uncertain us health care vote mar   at  am et by michael ashbaugh opinion harry boxer’s six biotechnology stocks to watch mar   at  pm et by harry boxer opinion four biotech stocks surging on optimism about drug trials product launches mar   at  am et by harry boxer amicus therapeutics upgraded to outperform from neutral at rw baird jan   at  am et by tomi kilgore amicus shares drop  after fda denies quick drug approval nov   at  pm et by wallace witkowski some biotechnology stocks that provide ‘clear opportunities’ jp morgan says feb   at  am et by emma court  stocks to watch sep   at  pm et by harry boxer  stocks to watch jul   at  pm et by harry boxer six stocks to watch jul   at  pm et by harry boxer nike shares rise after profit beat revenue miss mar   at  pm et by wallace witkowski amicus therapeutics shares rally on news of positive regulatory meetings mar   at  am et by ciara linnane lazboy shares rally after earnings beat targets nov   at  pm et by sue chang urban outfitters slides after earnings miss expectations nov   at  pm et by sue chang apple sets intraday record petsmart considers sale aug   at  pm et by ben eisen amicus therapeutics shares up  in premarket trade aug   at  am et by ciara linnane amicus therapeutic’s fabry treatment meets goals in latestage trial aug   at  am et by michael calia us stocks rise as risk appetite returns apr   at  pm et by anora mahmudova charting the market a graphic look at selected stock activity for the week ended july   includes nrg energy snap and michael kors jul   at  pm et on barrons online amicus gets nod from fda to submit experimental drug for approval a biotechnology company said the us food and drug administration allowed it to submit an experimental drug for approval without running an additional clinical study that the agency previously demanded jul   at  pm et on the wall street journal stocks to watch pepsico snap barracuda networks rentacenter jc penney among the companies with shares expected to trade actively in monday’s session are pepsico inc snap inc barracuda networks inc and rentacenter inc jul   at  am et on the wall street journal one thing is certain  will be year of uncertainty for ceos dec   at  pm et on the wall street journal amicus therapeutics’ fabry drug moves closer to european approval apr   at  pm et on the wall street journal stocks to watch valeant honeywell united technologies dollar tree mar   at  am et on the wall street journal stocks to watch twitter ge att brink’s oct   at  am et on the wall street journal amicus sees delay in us approval of drug oct   at  pm et on the wall street journal hillary clinton tweet sends biotech stocks tumbling sep   at  pm et on the wall street journal stocks fall to cap turbulent month aug   at  pm et on the wall street journal one dad’s year quest for children’s cure dec   at  pm et on the wall street journal stocks to watch sprint goodyear mgm resorts apr   at  am et on the wall street journal amicus reports positive results for fabry treatment apr   at  am et on the wall street journal stocks to watch finish line accuray coinstar jan   at  am et on the wall street journal stocks stage late rally dec   at  pm et on the wall street journal stocks to watch nyse euronext arris group vivus dec   at  am et on the wall street journal stocks to watch sprint metropcs ruby tuesday oct   at  am et on the wall street journal china distance education holdings amicus therapeutics biggest price decliners dl fold oct   at  pm et on the wall street journal granite construction amicus therapeutics biggest price decliners gva fold oct   at  pm et on the wall street journal amicus finds a friend in shire nov   at  pm et on the wall street journal recent news other news press releases is the fda biotechs best friend is the fda biotechs best friend jul   at  am et on seeking alpha daily insider ratings round up  fold kin iff cvo mmac ystr daily insider ratings round up  fold kin iff cvo mmac ystr jul   at  am et on seeking alpha after yuge rally what now for amicus therapeutics after yuge rally what now for amicus therapeutics jul   at  am et on seeking alpha no surprise amicus therapeutics hits up investors for more cash jul   at  pm et on motley fool wall street opens stable with yellen in nd day of testimony wall street opens stable with yellen in nd day of testimony jul   at  am et on gurufocuscom biotech forum daily digest  new leadership at teva a trading idea for agenus biotech forum daily digest  new leadership at teva a trading idea for agenus jul   at  am et on seeking alpha amicus prices stock offering at  shares off  premarket amicus prices stock offering at  shares off  premarket jul   at  am et on seeking alpha company news for july   companies in the news are foldslparnaevgnmon jul   at  am et on zackscom biotech stock roundup arena shoots up on study data celg inks immunooncology deal arena arna saw it shares shoot up on midstage data on its pulmonary arterial hypertension drug while quite a few companies provided regulatory updates jul   at  am et on zackscom amicus  updates to thesis fda does a  amicus  updates to thesis fda does a  jul   at  am et on seeking alpha amicus  updates to thesis fda does a  amicus  updates to thesis fda does a  jul   at  am et on seeking alpha watch these  huge call purchases in wednesday trade watch these  huge call purchases in wednesday trade jul   at  am et on benzingacom watch these  huge call purchases in wednesday trade watch these  huge call purchases in wednesday trade jul   at  am et on benzingacom how big is amicus therapeutics galafold opportunity in the us jul   at  pm et on motley fool amicus gets nod from fda to submit experimental drug for approval a biotechnology company said the us food and drug administration allowed it to submit an experimental drug for approval without running an additional clinical study that the agency previously demanded jul   at  pm et on the wall street journal benzingas option alert recap from july  benzingas option alert recap from july  jul   at  pm et on benzingacom benzingas option alert recap from july  benzingas option alert recap from july  jul   at  pm et on benzingacom why halcon resources amicus therapeutics and rentacenter jumped today jul   at  pm et on motley fool galafold reversal should gladden rare disease companies galafold reversal should gladden rare disease companies jul   at  pm et on seeking alpha amicus nda submission proves it is the king of treating fabry disease amicus nda submission proves it is the king of treating fabry disease jul   at  pm et on seeking alpha amicus therapeutics announces closing of underwritten offering of common stock and full exercise of option to purchase additional shares amicus therapeutics announces closing of underwritten offering of common stock and full exercise of option to purchase additional shares jul   at  am et on globenewswire technical reports on biotech equities  amicus therapeutics pulmatrix amgen and bioverativ technical reports on biotech equities  amicus therapeutics pulmatrix amgen and bioverativ jul   at  am et on pr newswire  prf amicus therapeutics prices underwritten offering of common stock amicus therapeutics prices underwritten offering of common stock jul   at  pm et on globenewswire amicus therapeutics announces public offering of common stock amicus therapeutics announces public offering of common stock jul   at  pm et on globenewswire biotech stocks ride momentum in anticipation of favorable governmental policy environment biotech stocks ride momentum in anticipation of favorable governmental policy environment jul   at  am et on pr newswire  prf todays research reports on stocks to watch amicus therapeutics inc and novocure ltd todays research reports on stocks to watch amicus therapeutics inc and novocure ltd jul   at  am et on accesswire us fda confirms amicus therapeutics may submit new drug application for migalastat for fabry disease us fda confirms amicus therapeutics may submit new drug application for migalastat for fabry disease jul   at  am et on globenewswire amicus therapeutics submits japanese new drug application for migalastat for fabry disease amicus therapeutics submits japanese new drug application for migalastat for fabry disease jun   at  am et on globenewswire breakfast technical briefing on biotech stocks  celsci amicus therapeutics galena biopharma and cleveland biolabs breakfast technical briefing on biotech stocks  celsci amicus therapeutics galena biopharma and cleveland biolabs jun   at  am et on pr newswire  prf amicus therapeutics to present at goldman sachs th annual global healthcare conference amicus therapeutics to present at goldman sachs th annual global healthcare conference jun   at  am et on globenewswire amicus therapeutics receives rare pediatric disease designation for sd for patients with epidermolysis bullosa amicus therapeutics receives rare pediatric disease designation for sd for patients with epidermolysis bullosa may   at  am et on globenewswire amicus therapeutics announces planned analysis of primary endpoints in phase  epidermolysis bullosa study amicus therapeutics announces planned analysis of primary endpoints in phase  epidermolysis bullosa study may   at  am et on globenewswire todays research reports on biotech stocks to watch exelixis and amicus therapeutics todays research reports on biotech stocks to watch exelixis and amicus therapeutics may   at  am et on accesswire amicus therapeutics announces positive functional data from initial patients in pompe phase  study amicus therapeutics announces positive functional data from initial patients in pompe phase  study may   at  am et on globenewswire amicus therapeutics to present at two upcoming investor conferences amicus therapeutics to present at two upcoming investor conferences may   at  am et on globenewswire investor network amicus therapeutics inc to host earnings call investor network amicus therapeutics inc to host earnings call may   at  am et on accesswire amicus therapeutics announces first quarter  financial results and corporate updates amicus therapeutics announces first quarter  financial results and corporate updates may   at  am et on globenewswire amicus therapeutics to announce first quarter  financial results on may   amicus therapeutics to announce first quarter  financial results on may   may   at  pm et on globenewswire amicus therapeutics launches galafoldtm migalastat for treatment of fabry disease in france amicus therapeutics launches galafoldtm migalastat for treatment of fabry disease in france may   at  am et on globenewswire amicus therapeutics honors fabry disease awareness month and international pompe day apr   at  am et on globenewswire amicus therapeutics inc amicus therapeutics inc is a biotechnology company which is engaged in the discovery development and commercialization of novel treatments for patients living with rare and orphan diseases its product include migalastat hcl which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease the company was founded on february   and is headquartered in cranbury nj see full profile analyst ratings sell under hold over buy number of ratings  full ratings cowen analyst responds following amicus positive migalastat news jul   at  pm et on benzingacom amicus therapeutics heres the good news nov   at  pm et on benzingacom what are the next steps for amicus therapeutics migalastat nov   at  am et on benzingacom competitors name chg  market cap biomarin pharmaceutical inc  b shire plc adr  b biogen inc  b glaxosmithkline plc adr  b novo nordisk as adr  b competitor data provided by partner content trending tickers powered by lrcx  htht  jazz  cr  lite  advanced search stocks columns authors topics no results found video center learn morestoryful a division of news corp which owns marketwatch is a leading social media services company headquartered in dublin ireland storyful combines world class journalism with industryleading technology to discover verify and acquire original content and provide the ontheground sources news and media organizations need to tell the stories that matter to their audience stocks index  markets index bulletin investor alert stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies browse stocks stocks az abcdefghijklmnopqrstuvwxyzother browse by location argentina australia austria bahamas bahrain belgium bermuda botswana brazil british virgin islands canada cayman islands chile china colombia curacao cyprus czech republic denmark egypt estonia finland france germany gibraltar greece hong kong hungary iceland india indonesia ireland isle of man israel italy japan jordan kazakhstan kuwait latvia lebanon liechtenstein lithuania luxembourg malaysia malta mauritius mexico monaco money rates morocco namibia netherlands new zealand norway oman pakistan panama peru philippines poland portugal qatar romania russia saudi arabia singapore slovakia slovenia south africa south korea spain sri lanka sweden switzerland taiwan thailand tunisia turkey ukraine united arab emirates united states venezuela western samoa log in  am edt july   marketstatecountryus new york closed marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest ayour next online order could be picked out by a robot a costly mistakes people make when buying cars awhat’s a cameo – like ed sheeran on game of thrones – actually worth ptrump says he has ‘complete power to pardon’ plawmakers reach deal on russia sanctions bill reports palphabet earnings a  billion hit for google potential youtube results for investors pyou can date someone who looks just like donald trump with this new online service pwant to buy happiness splurge on these  things pthis is what people really buy when they emotionally overspend hint it’s not designer clothes pjohn mccain is a war hero — but think twice before saying he’s ‘battling’ cancer pthe dark side of cruises pi want to buy my brothers out of our family home — but they want me to pay future sales fees poj simpson made over  while in prison and won’t have to give any of it to the goldman family pnot even free money can make some people go to the gym phow realestate tv shows determine what buyers look for in a house pwhat eleanor roosevelt and helen gurley brown ate — and what we can learn from it pnote to parents this social network was rated the worst for teenage cyberbullying pif like sean spicer you suddenly quit your job — what should you do next pthis is the deadliest time of your life to put on weight p unfortunate reasons why millennials can’t have nice things or save any money loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  stocks index  markets index bulletin investor alert stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies browse stocks stocks az abcdefghijklmnopqrstuvwxyzother browse by location argentina australia austria bahamas bahrain belgium bermuda botswana brazil british virgin islands canada cayman islands chile china colombia curacao cyprus czech republic denmark egypt estonia finland france germany gibraltar greece hong kong hungary iceland india indonesia ireland isle of man israel italy japan jordan kazakhstan kuwait latvia lebanon liechtenstein lithuania luxembourg malaysia malta mauritius mexico monaco money rates morocco namibia netherlands new zealand norway oman pakistan panama peru philippines poland portugal qatar romania russia saudi arabia singapore slovakia slovenia south africa south korea spain sri lanka sweden switzerland taiwan thailand tunisia turkey ukraine united arab emirates united states venezuela western samoa log in  am edt july   marketstatecountryus new york closed marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest ayour next online order could be picked out by a robot a costly mistakes people make when buying cars awhat’s a cameo – like ed sheeran on game of thrones – actually worth ptrump says he has ‘complete power to pardon’ plawmakers reach deal on russia sanctions bill reports palphabet earnings a  billion hit for google potential youtube results for investors pyou can date someone who looks just like donald trump with this new online service pwant to buy happiness splurge on these  things pthis is what people really buy when they emotionally overspend hint it’s not designer clothes pjohn mccain is a war hero — but think twice before saying he’s ‘battling’ cancer pthe dark side of cruises pi want to buy my brothers out of our family home — but they want me to pay future sales fees poj simpson made over  while in prison and won’t have to give any of it to the goldman family pnot even free money can make some people go to the gym phow realestate tv shows determine what buyers look for in a house pwhat eleanor roosevelt and helen gurley brown ate — and what we can learn from it pnote to parents this social network was rated the worst for teenage cyberbullying pif like sean spicer you suddenly quit your job — what should you do next pthis is the deadliest time of your life to put on weight p unfortunate reasons why millennials can’t have nice things or save any money loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  stockscountryunited states index  markets index bulletin investor alert stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies location united states name exchange sector  communique laboratory inc ocqlf ootc software  property insurance holdings inc pih xnas nonlife insurance flowerscom inc cl a flws xnas specialty retail pm industries inc opmz ootc food products st capital bank ca fisb ootc banking st constitution bancorp fccy xnas banking st nrg corp fnrc ootc oil extraction st source corp srce xnas banking  motors inc etfm ootc automobiles st century fox inc cl a foxa xnas broadcasting st century fox inc cl b fox xnas broadcasting vianet group inc adr vnet xnas internetonline nd century group inc xxii xase biotechnology  kid doc inc tvmd ootc healthcare provision u inc twou xnas software xleveraged long etracs linked to wells fargo business development co index  bdcl arcx major international banks xleveraged long etracs wells fargo business development lbdc arcx major international banks d eye solutions inc tdey ootc motion picturesound recording d pioneer systems inc dpsm ootc software d systems corp ddd xnys computersconsumer electronics dicon corp tdcp ootc software dshoppingcom thds ootc mixed retailing dx industries inc dddx ootc computersconsumer electronics i group plc adr tgopy ootc finance companies m co mmm xnys diversified holding companies pea international inc tpnl xotc accounting power energy group inc pspw ootc renewable energy generation tl technologies corp ttmzf ootc advertisingmarketingpublic relations  property management inc ftpm ootc real estate agentsbrokers cable tv international inc catv ootc diversified business services licensing corp fourq ootc diversified business services com ltd adr wbai xnys gambling industries job inc adr jobs xnas employmenttraining services com inc adr wuba xnys consumer services barz international inc barz ootc networking n plus inc fplsf ootc commodity chemicals d global technologies inc sixd ootc computer services  renewable energy corp rnwr ootc multiutilities  energy ltd adr tngry ootc oil extraction  holdings plc eihdf ootc gambling industries point energy partners lp cafd xnas renewable energy generation x inc eght xnas wired telecommunications services a clean slate inc drwn ootc diversified business services aw revenue royalties income fund awrrf ootc restaurants a h belo corp series a ahc xnys publishing a schulman inc shlm xnas commodity chemicals a schulman inc  pfd slmnp ootc commodity chemicals ad makepeace co make ootc farming am castle  co cas xnys wholesalers ao smith corp aos xnys building materialsproducts ap moellermaersk as adr amkby ootc water transportshipping ap moellermaersk as series a amkaf ootc water transportshipping ap moellermaersk as series b amkbf ootc water transportshipping as roma spa asraf ootc recreational services a group inc awon ootc tobacco a networks inc aten xnys computer services a milk co ltd acopf ootc biotechnology aac holdings inc aac xnys healthcare provision aac technologies holdings inc aacaf ootc industrial electronics aac technologies holdings inc adr aacay ootc industrial electronics aaon inc aaon xnas building materialsproducts aap inc aapj ootc food products aar corp air xnys aerospace productsparts aarons inc aan xnys consumer services ab science sa abscf ootc pharmaceuticals ab svensk exportkredit elements linked to mlcx biofuels index total return fue arcx finance companies ab svensk exportkredit elements linked to mlcx grain index total return gru arcx finance companies abt financial corp abto ootc banking abacus mining  exploration corp abcff ootc general mining abakan inc abki ootc industrial products abattis bioceuticals corp attbf ootc biotechnology abaxis inc abax xnas medical equipmentsupplies abb ltd ablzf ootc industrial machinery abb ltd adr abb xnys industrial machinery abbott laboratories abt xnys pharmaceuticals abbvie inc abbv xnys biotechnology abby inc abby ootc oil extraction abcam plc abczf ootc biotechnology abcam plc adr abczy ootc biotechnology abco energy inc abce ootc industrial machinery abcourt mines inc abmbf ootc general mining aben resources ltd abnaf ootc general mining abengoa sa b agoaf ootc construction abeona therapeutics inc abeo xnas biotechnology abeona therapeutics inc wt abeow xnas abercrombie  fitch co anf xnys clothing retail aberdeen asiapacific income fund inc fax xase closedend funds aberdeen asiapacific income investment co ltd abakf ootc closedend funds aberdeen asset management plc abdnf ootc investment advisors aberdeen asset management plc adr abdny ootc investment advisors aberdeen australia equity fund inc iaf xase closedend funds aberdeen chile fund inc ch xase closedend funds aberdeen emerging markets smaller company opportunities fund inc abe xase closedend funds aberdeen global income fund inc fco xase closedend funds aberdeen greater china fund inc gch xnys closedend funds aberdeen indonesia fund inc if xase closedend funds aberdeen international inc aabvf ootc general mining aberdeen israel fund inc isl xase closedend funds aberdeen japan equity fund inc jeq xnys closedend funds aberdeen latin america equity fund inc laq xase closedend funds aberdeen singapore fund inc sgf xnys closedend funds abertis infraestructuras sa adr abrty ootc transportation services ability inc abil xnas precision products ability inc wt abiwf ootc abiomed inc abmd xnas medical equipmentsupplies abitibi royalties inc atbyf ootc general mining able energy inc able ootc gas utilities ablynx nv ablyf ootc biotechnology abm industries inc abm xnys diversified business services abraxas petroleum corp axas xnas oil extraction absecon bancorp ascn ootc banking absolute health  fitness inc ahfi ootc recreational services absolute software corp alswf ootc software abt holdings inc abot ootc precious metals abtech holdings inc abhd ootc industrial machinery abv consulting inc abvn ootc advertisingmarketingpublic relations ac immune sa aciu xnas biotechnology acacia communications inc acia xnas networking acacia diversified holdings inc acca ootc specialty retail acacia mining plc abglf ootc gold acacia research corp  acacia technologies actg xnas diversified business services acadia healthcare co inc achc xnas healthcare provision acadia pharmaceuticals inc acad xnas biotechnology acadia realty trust akr xnys acadian timber corp acazf ootc forestry  wood products acasti pharma inc acst xnas pharmaceuticals accelera innovations inc acnv ootc healthcare provision accelerate diagnostics inc axdx xnas biotechnology accelerize inc aclz xotc life insurance acceleron pharma inc xlrn xnas biotechnology accenture plc cl a acn xnys diversified business services access national corp ancx xnas banking access power inc accr ootc wired telecommunications services access worldwide communications inc awwc ootc advertisingmarketingpublic relations acciona sa acxif ootc construction acco brands corp acco xnys nondurable household products accor sa acrff ootc hotels accor sa adr accyy ootc hotels accordia golf co ltd acgff ootc recreational services accredited mortgage loan reit trust  perp cum pfd series a ahhap ootc mortgages accretive health inc achi ootc healthcare provision accuray inc aray xnas medical equipmentsupplies accuride corp acw xnys auto  commercial vehicle parts acelrx pharmaceuticals inc acrx xnas pharmaceuticals acer inc gdr reg s aceyy ootc computersconsumer electronics acerus pharmaceuticals corp trlpf ootc biotechnology aceto corp acet xnas specialty chemicals achaogen inc akao xnas biotechnology achillion pharmaceuticals inc achn xnas biotechnology aci worldwide inc aciw xnas software «» log in  am edt july   marketstatecountryus new york closed marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest ayour next online order could be picked out by a robot a costly mistakes people make when buying cars awhat’s a cameo – like ed sheeran on game of thrones – actually worth ptrump says he has ‘complete power to pardon’ plawmakers reach deal on russia sanctions bill reports palphabet earnings a  billion hit for google potential youtube results for investors pyou can date someone who looks just like donald trump with this new online service pwant to buy happiness splurge on these  things pthis is what people really buy when they emotionally overspend hint it’s not designer clothes pjohn mccain is a war hero — but think twice before saying he’s ‘battling’ cancer pthe dark side of cruises pi want to buy my brothers out of our family home — but they want me to pay future sales fees poj simpson made over  while in prison and won’t have to give any of it to the goldman family pnot even free money can make some people go to the gym phow realestate tv shows determine what buyers look for in a house pwhat eleanor roosevelt and helen gurley brown ate — and what we can learn from it pnote to parents this social network was rated the worst for teenage cyberbullying pif like sean spicer you suddenly quit your job — what should you do next pthis is the deadliest time of your life to put on weight p unfortunate reasons why millennials can’t have nice things or save any money loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  fold stock price  amicus therapeutics inc stock quote us nasdaq  marketwatch sections watchlist signup • login search bulletin us europe asia fx rates futures range d d m m m y y djia f    sp f    nasdaq f    gold    silver    crude oil    sp  movers ctas  cof  etfc  syf  hp  isrg  hban  chk  latest newsall times eastern a your next online order could be picked out by a robot a  costly mistakes people make when buying cars a what’s a cameo – like ed sheeran on game of thrones – actually worth  updated trump says he has ‘complete power to pardon’  lawmakers reach deal on russia sanctions bill reports  alphabet earnings a  billion hit for google potential youtube results for investors  updated you can date someone who looks just like donald trump with this new online service  updated want to buy happiness splurge on these  things  this is what people really buy when they emotionally overspend hint it’s not designer clothes  updated john mccain is a war hero — but think twice before saying he’s ‘battling’ cancer to be replaced home investing quotes stocks united states fold overview compare quotes stock screener earnings calendar sectors nasdaq fold us nasdaq join td ameritrade find a broker amicus therapeutics inc watchlist createfoldalert after hours last updated jul    pm edt delayed quote     after hours volume k close chg chg     advanced charting d d m m m ytd y y all   vol advanced charting  vs avg volume m  day avg  m open  close   day lowhigh  day range   week lowhigh  your watchlist customize marketwatch have watchlists log in to see them here or sign up to get started create account … or log in symbol last chg chg  no items in watchlist there are currently no items in this watchlist add ticker to watchlist go to your watchlist no saved watchlists create a list of the investments you want to track create watchlist …or try this starter list uh oh something went wrong while loading watchlist go to watchlist recently viewed tickers no recent tickers visit a quote page and your recently viewed tickers will be displayed here search tickers overview profile news charts financials historical quotes analyst estimates options sec filings insiders key data open  day range     week range    market cap b shares outstanding m public float m beta  rev per employee k pe ratio na eps  yield na dividend na exdividend date na short interest m   of float shorted  average volume m performance  day   month   month  ytd   year  recent news marketwatch other dow jones nasdaq extends win streak as stocks digest latest political drama jul   at  pm et by victor reklaitis amicus therapeuticss stock soars on heavy volume after fda clears nda submission for fabry disease treatment shares of amicus therapeutics inc shot up  toward a month high in active premarket trade tuesday after the biotechnology company said the food and drug administration cleared the company to submit a new drug application for its fabry disease treatment volume approached  shares about  minutes before the open making the stock the most actively traded in the premarket session the company said it plans to submit an nda for oral precision medicine migalastat in the fourth quarter of  we are moving ahead expeditiously with our nda submission and accelerating the us pathway for migalastat said chief executive john crowley today is a seminal moment in the development of migalastat and a testament to the dedication and perseverance of the patients physicians and employees who have worked so hard on the development of this precision medicine the stock had doubled year to date through monday while the ishares nasdaq biotechnology etf has climbed  and the sp  has gained  jul   at  am et by tomi kilgore amicus therapeutics stock soars  premarket after fda oks nda submission for fabry disease treatment amicus therapeutics stock soars  premarket after fda oks nda submission for fabry disease treatment jul   at  am et by tomi kilgore charting the technical overhang amid an uncertain us health care vote mar   at  am et by michael ashbaugh opinion harry boxer’s six biotechnology stocks to watch mar   at  pm et by harry boxer opinion four biotech stocks surging on optimism about drug trials product launches mar   at  am et by harry boxer amicus therapeutics upgraded to outperform from neutral at rw baird jan   at  am et by tomi kilgore amicus shares drop  after fda denies quick drug approval nov   at  pm et by wallace witkowski some biotechnology stocks that provide ‘clear opportunities’ jp morgan says feb   at  am et by emma court  stocks to watch sep   at  pm et by harry boxer  stocks to watch jul   at  pm et by harry boxer six stocks to watch jul   at  pm et by harry boxer nike shares rise after profit beat revenue miss mar   at  pm et by wallace witkowski amicus therapeutics shares rally on news of positive regulatory meetings mar   at  am et by ciara linnane lazboy shares rally after earnings beat targets nov   at  pm et by sue chang urban outfitters slides after earnings miss expectations nov   at  pm et by sue chang apple sets intraday record petsmart considers sale aug   at  pm et by ben eisen amicus therapeutics shares up  in premarket trade aug   at  am et by ciara linnane amicus therapeutic’s fabry treatment meets goals in latestage trial aug   at  am et by michael calia us stocks rise as risk appetite returns apr   at  pm et by anora mahmudova charting the market a graphic look at selected stock activity for the week ended july   includes nrg energy snap and michael kors jul   at  pm et on barrons online amicus gets nod from fda to submit experimental drug for approval a biotechnology company said the us food and drug administration allowed it to submit an experimental drug for approval without running an additional clinical study that the agency previously demanded jul   at  pm et on the wall street journal stocks to watch pepsico snap barracuda networks rentacenter jc penney among the companies with shares expected to trade actively in monday’s session are pepsico inc snap inc barracuda networks inc and rentacenter inc jul   at  am et on the wall street journal one thing is certain  will be year of uncertainty for ceos dec   at  pm et on the wall street journal amicus therapeutics’ fabry drug moves closer to european approval apr   at  pm et on the wall street journal stocks to watch valeant honeywell united technologies dollar tree mar   at  am et on the wall street journal stocks to watch twitter ge att brink’s oct   at  am et on the wall street journal amicus sees delay in us approval of drug oct   at  pm et on the wall street journal hillary clinton tweet sends biotech stocks tumbling sep   at  pm et on the wall street journal stocks fall to cap turbulent month aug   at  pm et on the wall street journal one dad’s year quest for children’s cure dec   at  pm et on the wall street journal stocks to watch sprint goodyear mgm resorts apr   at  am et on the wall street journal amicus reports positive results for fabry treatment apr   at  am et on the wall street journal stocks to watch finish line accuray coinstar jan   at  am et on the wall street journal stocks stage late rally dec   at  pm et on the wall street journal stocks to watch nyse euronext arris group vivus dec   at  am et on the wall street journal stocks to watch sprint metropcs ruby tuesday oct   at  am et on the wall street journal china distance education holdings amicus therapeutics biggest price decliners dl fold oct   at  pm et on the wall street journal granite construction amicus therapeutics biggest price decliners gva fold oct   at  pm et on the wall street journal amicus finds a friend in shire nov   at  pm et on the wall street journal recent news other news press releases is the fda biotechs best friend is the fda biotechs best friend jul   at  am et on seeking alpha daily insider ratings round up  fold kin iff cvo mmac ystr daily insider ratings round up  fold kin iff cvo mmac ystr jul   at  am et on seeking alpha after yuge rally what now for amicus therapeutics after yuge rally what now for amicus therapeutics jul   at  am et on seeking alpha no surprise amicus therapeutics hits up investors for more cash jul   at  pm et on motley fool wall street opens stable with yellen in nd day of testimony wall street opens stable with yellen in nd day of testimony jul   at  am et on gurufocuscom biotech forum daily digest  new leadership at teva a trading idea for agenus biotech forum daily digest  new leadership at teva a trading idea for agenus jul   at  am et on seeking alpha amicus prices stock offering at  shares off  premarket amicus prices stock offering at  shares off  premarket jul   at  am et on seeking alpha company news for july   companies in the news are foldslparnaevgnmon jul   at  am et on zackscom biotech stock roundup arena shoots up on study data celg inks immunooncology deal arena arna saw it shares shoot up on midstage data on its pulmonary arterial hypertension drug while quite a few companies provided regulatory updates jul   at  am et on zackscom amicus  updates to thesis fda does a  amicus  updates to thesis fda does a  jul   at  am et on seeking alpha amicus  updates to thesis fda does a  amicus  updates to thesis fda does a  jul   at  am et on seeking alpha watch these  huge call purchases in wednesday trade watch these  huge call purchases in wednesday trade jul   at  am et on benzingacom watch these  huge call purchases in wednesday trade watch these  huge call purchases in wednesday trade jul   at  am et on benzingacom how big is amicus therapeutics galafold opportunity in the us jul   at  pm et on motley fool amicus gets nod from fda to submit experimental drug for approval a biotechnology company said the us food and drug administration allowed it to submit an experimental drug for approval without running an additional clinical study that the agency previously demanded jul   at  pm et on the wall street journal benzingas option alert recap from july  benzingas option alert recap from july  jul   at  pm et on benzingacom benzingas option alert recap from july  benzingas option alert recap from july  jul   at  pm et on benzingacom why halcon resources amicus therapeutics and rentacenter jumped today jul   at  pm et on motley fool galafold reversal should gladden rare disease companies galafold reversal should gladden rare disease companies jul   at  pm et on seeking alpha amicus nda submission proves it is the king of treating fabry disease amicus nda submission proves it is the king of treating fabry disease jul   at  pm et on seeking alpha amicus therapeutics announces closing of underwritten offering of common stock and full exercise of option to purchase additional shares amicus therapeutics announces closing of underwritten offering of common stock and full exercise of option to purchase additional shares jul   at  am et on globenewswire technical reports on biotech equities  amicus therapeutics pulmatrix amgen and bioverativ technical reports on biotech equities  amicus therapeutics pulmatrix amgen and bioverativ jul   at  am et on pr newswire  prf amicus therapeutics prices underwritten offering of common stock amicus therapeutics prices underwritten offering of common stock jul   at  pm et on globenewswire amicus therapeutics announces public offering of common stock amicus therapeutics announces public offering of common stock jul   at  pm et on globenewswire biotech stocks ride momentum in anticipation of favorable governmental policy environment biotech stocks ride momentum in anticipation of favorable governmental policy environment jul   at  am et on pr newswire  prf todays research reports on stocks to watch amicus therapeutics inc and novocure ltd todays research reports on stocks to watch amicus therapeutics inc and novocure ltd jul   at  am et on accesswire us fda confirms amicus therapeutics may submit new drug application for migalastat for fabry disease us fda confirms amicus therapeutics may submit new drug application for migalastat for fabry disease jul   at  am et on globenewswire amicus therapeutics submits japanese new drug application for migalastat for fabry disease amicus therapeutics submits japanese new drug application for migalastat for fabry disease jun   at  am et on globenewswire breakfast technical briefing on biotech stocks  celsci amicus therapeutics galena biopharma and cleveland biolabs breakfast technical briefing on biotech stocks  celsci amicus therapeutics galena biopharma and cleveland biolabs jun   at  am et on pr newswire  prf amicus therapeutics to present at goldman sachs th annual global healthcare conference amicus therapeutics to present at goldman sachs th annual global healthcare conference jun   at  am et on globenewswire amicus therapeutics receives rare pediatric disease designation for sd for patients with epidermolysis bullosa amicus therapeutics receives rare pediatric disease designation for sd for patients with epidermolysis bullosa may   at  am et on globenewswire amicus therapeutics announces planned analysis of primary endpoints in phase  epidermolysis bullosa study amicus therapeutics announces planned analysis of primary endpoints in phase  epidermolysis bullosa study may   at  am et on globenewswire todays research reports on biotech stocks to watch exelixis and amicus therapeutics todays research reports on biotech stocks to watch exelixis and amicus therapeutics may   at  am et on accesswire amicus therapeutics announces positive functional data from initial patients in pompe phase  study amicus therapeutics announces positive functional data from initial patients in pompe phase  study may   at  am et on globenewswire amicus therapeutics to present at two upcoming investor conferences amicus therapeutics to present at two upcoming investor conferences may   at  am et on globenewswire investor network amicus therapeutics inc to host earnings call investor network amicus therapeutics inc to host earnings call may   at  am et on accesswire amicus therapeutics announces first quarter  financial results and corporate updates amicus therapeutics announces first quarter  financial results and corporate updates may   at  am et on globenewswire amicus therapeutics to announce first quarter  financial results on may   amicus therapeutics to announce first quarter  financial results on may   may   at  pm et on globenewswire amicus therapeutics launches galafoldtm migalastat for treatment of fabry disease in france amicus therapeutics launches galafoldtm migalastat for treatment of fabry disease in france may   at  am et on globenewswire amicus therapeutics honors fabry disease awareness month and international pompe day apr   at  am et on globenewswire amicus therapeutics inc amicus therapeutics inc is a biotechnology company which is engaged in the discovery development and commercialization of novel treatments for patients living with rare and orphan diseases its product include migalastat hcl which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease the company was founded on february   and is headquartered in cranbury nj see full profile analyst ratings sell under hold over buy number of ratings  full ratings cowen analyst responds following amicus positive migalastat news jul   at  pm et on benzingacom amicus therapeutics heres the good news nov   at  pm et on benzingacom what are the next steps for amicus therapeutics migalastat nov   at  am et on benzingacom competitors name chg  market cap biomarin pharmaceutical inc  b shire plc adr  b biogen inc  b glaxosmithkline plc adr  b novo nordisk as adr  b competitor data provided by partner content trending tickers powered by lrcx  htht  jazz  cr  lite  advanced search stocks columns authors topics no results found video center learn morestoryful a division of news corp which owns marketwatch is a leading social media services company headquartered in dublin ireland storyful combines world class journalism with industryleading technology to discover verify and acquire original content and provide the ontheground sources news and media organizations need to tell the stories that matter to their audience amicus therapeutics inc  product pipeline review   infowiseguyreportscom     chat with us           us         uk login register home report categories premium reports access to  premium reports aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports report categories aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports publisher knowledgestore countries browse by country browse by continent browse by group  region conferences upcoming conferences seminars conferences upcoming conferences seminars countries browse by country browse by continent browse by group  region news  blog press release blog news  blogs press release blogs faqs about us about our company our team life at wgr careers contact us there are no items currently in your basket there are no items currently in your basket search home all reports amicus therapeutics inc  product pipeline review   amicus therapeutics inc  product pipeline review   wgr  may  global  pages global markets direct description table of content sample report enquiry before buy related reports amicus therapeutics inc  product pipeline review  summaryglobal markets direct’s ‘amicus therapeutics inc  product pipeline review  ’ provides an overview of the amicus therapeutics inc’s pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of amicus therapeutics inc’s complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsglobal markets direct’s report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets direct’s proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets direct’s team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasescope the report provides brief overview of amicus therapeutics inc including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of amicus therapeutics inc’s human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones  special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement  latest news and deals relating to the amicus therapeutics inc’s pipeline productsreasons to buy evaluate amicus therapeutics inc’s strategic position with total access to detailed information on its product pipeline assess the growth potential of amicus therapeutics inc in its therapy areas of focus identify new drug targets and therapeutic classes in the amicus therapeutics inc’s rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of amicus therapeutics inc and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of amicus therapeutics inc develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of amicus therapeutics inc and identify potential opportunities in those areas avoid intellectual property rights related issues table of contentstable of contents list of tables list of figures amicus therapeutics inc snapshot amicus therapeutics inc overview key information key facts amicus therapeutics inc  research and development overview key therapeutic areas amicus therapeutics inc  pipeline review pipeline products by stage of development pipeline products  monotherapy pipeline products  combination treatment modalities pipeline products  partnered products partnered productscombination treatment modalities amicus therapeutics inc  pipeline products glance amicus therapeutics inc  late stage pipeline products phase iii productscombination treatment modalities amicus therapeutics inc  clinical stage pipeline products phase ii productscombination treatment modalities phase i productscombination treatment modalities amicus therapeutics inc  early stage pipeline products preclinical productscombination treatment modalities discovery productscombination treatment modalities amicus therapeutics inc  drug profiles migalastat hydrochloride product description mechanism of action rd progress afegostat tartrate product description mechanism of action rd progress duvoglustat hydrochloride  alglucosidase alfa product description mechanism of action rd progress migalastat hydrochloride  enzyme replacement therapy product description mechanism of action rd progress migalastat hydrochloride  agalsidase alfa product description mechanism of action rd progress at product description mechanism of action rd progress atb  chaperone product description mechanism of action rd progress chaperoneert combinations product description mechanism of action rd progress laronidase  chaperone product description mechanism of action rd progress recombinant enzyme for lysosomal storage disorder product description mechanism of action rd progress recombinant enzyme for gaucher disease product description mechanism of action rd progress amicus therapeutics inc  pipeline analysis amicus therapeutics inc  pipeline products by target amicus therapeutics inc  pipeline products by route of administration amicus therapeutics inc  pipeline products by molecule type amicus therapeutics inc  pipeline products by mechanism of action amicus therapeutics inc  recent pipeline updates amicus therapeutics inc  dormant projects amicus therapeutics inc  company statement amicus therapeutics inc  locations and subsidiaries head office other locations  subsidiaries appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tablesamicus therapeutics inc key information amicus therapeutics inc key facts amicus therapeutics inc  pipeline by indication  amicus therapeutics inc  pipeline by stage of development  amicus therapeutics inc  monotherapy products in pipeline  amicus therapeutics inc  combination treatment modalities in pipeline  amicus therapeutics inc  partnered products in pipeline  amicus therapeutics inc  partnered products combination treatment modalities  amicus therapeutics inc  phase iii  amicus therapeutics inc  phase ii  amicus therapeutics inc  phase i  amicus therapeutics inc  preclinical  amicus therapeutics inc  discovery  amicus therapeutics inc  pipeline by target  amicus therapeutics inc  pipeline by route of administration  amicus therapeutics inc  pipeline by molecule type  amicus therapeutics inc  pipeline products by mechanism of action  amicus therapeutics inc  recent pipeline updates  amicus therapeutics inc  dormant developmental projects amicus therapeutics inc subsidiaries list of figuresamicus therapeutics inc  pipeline by top  indication  amicus therapeutics inc  pipeline by stage of development  amicus therapeutics inc  monotherapy products in pipeline  amicus therapeutics inc  combination treatment modalities in pipeline  amicus therapeutics inc  pipeline by top  target  amicus therapeutics inc  pipeline by top  route of administration  amicus therapeutics inc  pipeline by top  molecule type  amicus therapeutics inc  pipeline products by top  mechanism of action   request a sample report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro do you have any specific field of interest confirm make an enquiry before buying this report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro your enquiry confirm purchase this market research report usd gbp euro yen inr user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  add to cart buy now   email report   sample report   save page   any questions   download information   check discount   download order form   email report   sample report   save page   any questions   download information   check discount   download order form contact us akash anand domain head business development saleswiseguyreportscom     us     uk rishabh arora domain head business development saleswiseguyreportscom  abu koshy domain head business development saleswiseguyreportscom     related reports × tell a friend about this report your name your email friends name friends email your enquiry send amicus therapeutics inc  product pipeline review   trends statistics segment and forecasts market size share analysis  market research store     gmt office hours  uscan toll free  us office no home categories become publisher news about us contact us select category consumer goods food  beverage heavy industry life sciences marketing  market research public sector service industries technology  media semiconductor chemical and materials metallurgical market research search home  life sciences  pharmaceuticals amicus therapeutics inc  product pipeline review   published jul  format pdf  global markets direct  number of pages   code mrs   report details table of content inquiry for buying request sample amicus therapeutics inc  product pipeline review   summary global markets direct’s ‘amicus therapeutics inc  product pipeline review  ’ provides an overview of the amicus therapeutics inc’s pharmaceutical research and development focus this report provides comprehensive information on the current therapeutic developmental pipeline of amicus therapeutics inc’s complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projects global markets direct’s report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets direct’s proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets direct’s team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass products note certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease scope  the report provides brief overview of amicus therapeutics inc including business description key information and facts and its locations and subsidiaries  the report reviews current pipeline of amicus therapeutics inc’s human therapeutic division and enlists all their major and minor projects  the report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones  special feature on outlicensed and partnered product portfolio  the report summarizes all the dormant and discontinued pipeline projects  latest company statement  latest news and deals relating to the amicus therapeutics inc’s pipeline products reasons to buy  evaluate amicus therapeutics inc’s strategic position with total access to detailed information on its product pipeline  assess the growth potential of amicus therapeutics inc in its therapy areas of focus  identify new drug targets and therapeutic classes in the amicus therapeutics inc’s rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas  exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps  develop strategic initiatives by understanding the focus areas of amicus therapeutics inc and exploit collaboration and partnership opportunities  identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage  plan mergers and acquisitions effectively by identifying the most promising pipeline of amicus therapeutics inc  develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope  explore the dormant and discontinued projects of amicus therapeutics inc and identify potential opportunities in those areas  avoid intellectual property rights related issues table of contents table of contents  list of tables  list of figures  amicus therapeutics inc snapshot  amicus therapeutics inc overview  key information  key facts  amicus therapeutics inc  research and development overview  key therapeutic areas  amicus therapeutics inc  pipeline review  pipeline products by stage of development  pipeline products  monotherapy  pipeline products  combination treatment modalities  pipeline products  partnered products  partnered productscombination treatment modalities  amicus therapeutics inc  pipeline products glance  amicus therapeutics inc  late stage pipeline products  preregistration productscombination treatment modalities  phase iii productscombination treatment modalities  amicus therapeutics inc  clinical stage pipeline products  phase ii productscombination treatment modalities  amicus therapeutics inc  early stage pipeline products  preclinical productscombination treatment modalities  amicus therapeutics inc  drug profiles  migalastat hydrochloride  product description  mechanism of action  rd progress  migalastat hydrochloride  agalsidase alfa  product description  mechanism of action  rd progress  duvoglustat hydrochloride  alglucosidase alfa  product description  mechanism of action  rd progress  duvoglustat hydrochloride  atb  product description  mechanism of action  rd progress  afegostat tartrate  product description  mechanism of action  rd progress  afegostat tartrate  ert  product description  mechanism of action  rd progress  at  product description  mechanism of action  rd progress  atb  product description  mechanism of action  rd progress  chaperoneert combinations  product description  mechanism of action  rd progress  laronidase  chaperone  product description  mechanism of action  rd progress  migalastat hydrochloride  enzyme replacement therapy biobetter  product description  mechanism of action  rd progress  recombinant enzyme for lysosomal storage disorder  product description  mechanism of action  rd progress  small molecule for neurodegenerative diseases  product description  mechanism of action  rd progress  amicus therapeutics inc  pipeline analysis  amicus therapeutics inc  pipeline products by target  amicus therapeutics inc  pipeline products by route of administration  amicus therapeutics inc  pipeline products by molecule type  amicus therapeutics inc  pipeline products by mechanism of action  amicus therapeutics inc  recent pipeline updates  amicus therapeutics inc  dormant projects  amicus therapeutics inc  company statement  amicus therapeutics inc  locations and subsidiaries  head office  other locations  subsidiaries  appendix  methodology  coverage  secondary research  primary research  expert panel validation  contact us  disclaimer  list of tables amicus therapeutics inc key information  amicus therapeutics inc key facts  amicus therapeutics inc  pipeline by indication   amicus therapeutics inc  pipeline by stage of development   amicus therapeutics inc  monotherapy products in pipeline   amicus therapeutics inc  combination treatment modalities in pipeline   amicus therapeutics inc  partnered products in pipeline   amicus therapeutics inc  partnered products combination treatment modalities   amicus therapeutics inc  preregistration   amicus therapeutics inc  phase iii   amicus therapeutics inc  phase ii   amicus therapeutics inc  preclinical   amicus therapeutics inc  pipeline by target   amicus therapeutics inc  pipeline by route of administration   amicus therapeutics inc  pipeline by molecule type   amicus therapeutics inc  pipeline products by mechanism of action   amicus therapeutics inc  recent pipeline updates   amicus therapeutics inc  dormant developmental projects  amicus therapeutics inc subsidiaries  list of figures amicus therapeutics inc  pipeline by top  indication   amicus therapeutics inc  pipeline by stage of development   amicus therapeutics inc  monotherapy products in pipeline   amicus therapeutics inc  combination treatment modalities in pipeline   amicus therapeutics inc  pipeline by top  target   amicus therapeutics inc  pipeline by top  route of administration   amicus therapeutics inc  pipeline by top  molecule type   amicus therapeutics inc  pipeline products by top  mechanism of action   inquiry for buying please fill your details below to inquire about this report  indicates required fields name email phone name of company titledesignation country name select country andorra united arab emirates afghanistan antigua and barbuda anguilla albania armenia angola antarctica argentina american samoa austria australia aruba åland islands azerbaijan bosnia and herzegovina barbados bangladesh belgium burkina faso bulgaria bahrain burundi benin saint barthélemy bermuda brunei darussalam bolivia plurinational state of bonaire sint eustatius and saba brazil bahamas bhutan bouvet island botswana belarus belize canada cocos keeling islands congo the democratic republic of the central african republic congo switzerland côte divoire cook islands chile cameroon china colombia costa rica cuba cape verde curaçao christmas island cyprus czech republic germany djibouti denmark dominica dominican republic algeria ecuador estonia egypt western sahara eritrea spain ethiopia finland fiji falkland islands malvinas micronesia federated states of faroe islands france gabon united kingdom grenada georgia french guiana guernsey ghana gibraltar greenland gambia guinea guadeloupe equatorial guinea greece south georgia and the south sandwich islands guatemala guam guineabissau guyana hong kong heard island and mcdonald islands honduras croatia haiti hungary indonesia ireland israel isle of man india british indian ocean territory iraq iran islamic republic of iceland italy jersey jamaica jordan japan kenya kyrgyzstan cambodia kiribati comoros saint kitts and nevis korea democratic peoples republic of korea republic of kuwait cayman islands kazakhstan lao peoples democratic republic lebanon saint lucia liechtenstein sri lanka liberia lesotho lithuania luxembourg latvia libya morocco monaco moldova republic of montenegro saint martin french part madagascar marshall islands macedonia the former yugoslav republic of mali myanmar mongolia macao northern mariana islands martinique mauritania montserrat malta mauritius maldives malawi mexico malaysia mozambique namibia new caledonia niger norfolk island nigeria nicaragua netherlands norway nepal nauru niue new zealand oman panama peru french polynesia papua new guinea philippines pakistan poland saint pierre and miquelon pitcairn puerto rico palestinian state of portugal palau paraguay qatar réunion romania serbia russian federation rwanda saudi arabia solomon islands seychelles sudan sweden singapore saint helena ascension and tristan da cunha slovenia svalbard and jan mayen slovakia sierra leone san marino senegal somalia suriname south sudan sao tome and principe el salvador sint maarten dutch part syrian arab republic swaziland turks and caicos islands chad french southern territories togo thailand tajikistan tokelau timorleste turkmenistan tunisia tonga turkey trinidad and tobago tuvalu taiwan province of china tanzania united republic of ukraine uganda united states minor outlying islands united states uruguay uzbekistan holy see vatican city state saint vincent and the grenadines venezuela bolivarian republic of virgin islands british virgin islands us viet nam vanuatu wallis and futuna samoa yemen mayotte south africa zambia zimbabwe how can we help you refresh captcha submit request sample please fill your details below to receive sample report  indicates required fields name email phone name of company titledesignation country name select country andorra united arab emirates afghanistan antigua and barbuda anguilla albania armenia angola antarctica argentina american samoa austria australia aruba åland islands azerbaijan bosnia and herzegovina barbados bangladesh belgium burkina faso bulgaria bahrain burundi benin saint barthélemy bermuda brunei darussalam bolivia plurinational state of bonaire sint eustatius and saba brazil bahamas bhutan bouvet island botswana belarus belize canada cocos keeling islands congo the democratic republic of the central african republic congo switzerland côte divoire cook islands chile cameroon china colombia costa rica cuba cape verde curaçao christmas island cyprus czech republic germany djibouti denmark dominica dominican republic algeria ecuador estonia egypt western sahara eritrea spain ethiopia finland fiji falkland islands malvinas micronesia federated states of faroe islands france gabon united kingdom grenada georgia french guiana guernsey ghana gibraltar greenland gambia guinea guadeloupe equatorial guinea greece south georgia and the south sandwich islands guatemala guam guineabissau guyana hong kong heard island and mcdonald islands honduras croatia haiti hungary indonesia ireland israel isle of man india british indian ocean territory iraq iran islamic republic of iceland italy jersey jamaica jordan japan kenya kyrgyzstan cambodia kiribati comoros saint kitts and nevis korea democratic peoples republic of korea republic of kuwait cayman islands kazakhstan lao peoples democratic republic lebanon saint lucia liechtenstein sri lanka liberia lesotho lithuania luxembourg latvia libya morocco monaco moldova republic of montenegro saint martin french part madagascar marshall islands macedonia the former yugoslav republic of mali myanmar mongolia macao northern mariana islands martinique mauritania montserrat malta mauritius maldives malawi mexico malaysia mozambique namibia new caledonia niger norfolk island nigeria nicaragua netherlands norway nepal nauru niue new zealand oman panama peru french polynesia papua new guinea philippines pakistan poland saint pierre and miquelon pitcairn puerto rico palestinian state of portugal palau paraguay qatar réunion romania serbia russian federation rwanda saudi arabia solomon islands seychelles sudan sweden singapore saint helena ascension and tristan da cunha slovenia svalbard and jan mayen slovakia sierra leone san marino senegal somalia suriname south sudan sao tome and principe el salvador sint maarten dutch part syrian arab republic swaziland turks and caicos islands chad french southern territories togo thailand tajikistan tokelau timorleste turkmenistan tunisia tonga turkey trinidad and tobago tuvalu taiwan province of china tanzania united republic of ukraine uganda united states minor outlying islands united states uruguay uzbekistan holy see vatican city state saint vincent and the grenadines venezuela bolivarian republic of virgin islands british virgin islands us viet nam vanuatu wallis and futuna samoa yemen mayotte south africa zambia zimbabwe how can we help you refresh captcha submit related reports global oncology market to   robust growth driven by rising prevalence and increased uptake of immune checkpoint inhibitors jun  gbi research  pages    code  mrs   global oncology market to   robust growth driven by rising prevalence and increased uptake of immune checkpoint inhibitors summary in  there were  million people living with any type of cancer within five years of diagnosis these are generally incurable once they progress to the stage where they are unresectable chemotherapy compounds are a mainstay treatment for cancers of all types at various disease stages in a typical course of therapy for cancer multiple chemothera read more interleukin  receptor subunit alpha cdw or cd or ilr  pipeline review h  jul  global markets direct  pages    code  mrs   interleukin  receptor subunit alpha cdw or cd or ilr  pipeline review h  summary interleukin  receptor subunit alpha cdw or cd or ilr  interleukin receptor is a protein found on the surface of cells it is a receptor for interleukin it acts as a receptor for thymic stromal lymphopoietin tslp it plays an important role in tcell acute lymphoblastic leukemia multiple sclerosis rheumatoid arthritis and juvenile idiopathic arthritis interleukin  recep read more  kda glucose regulated protein endoplasmic reticulum lumenal ca binding protein grp or heat shock  kda protein  or immunoglobulin heavy chain binding protein or hspa  pipeline review h  jul  global markets direct  pages    code  mrs    kda glucose regulated protein endoplasmic reticulum lumenal ca binding protein grp or heat shock  kda protein  or immunoglobulin heavy chain binding protein or hspa  pipeline review h  summary  kda glucose regulated protein endoplasmic reticulum lumenal ca binding protein grp or heat shock  kda protein  or immunoglobulin heavy chain binding protein or hspa pipeline target constitutes close to  molecules out of which approximately  molecules are devel read more survival motor neuron protein component of gems  or gemin  or smn or smn  pipeline review h  jul  global markets direct  pages    code  mrs   survival motor neuron protein component of gems  or gemin  or smn or smn  pipeline review h  summary according to the recently published report survival motor neuron protein  pipeline review h  survival motor neuron protein component of gems  or gemin  or smn or smn pipeline target constitutes close to  molecules out of which approximately  molecules are developed by companies and remaining by the universitiesinstitutes survival motor neuron protein  read more rho associated protein kinase  renal carcinoma antigen ny ren  or rho associated coiled coil containing protein kinase  or p rock  or rock or ec   pipeline review h  jul  global markets direct  pages    code  mrs   rho associated protein kinase  renal carcinoma antigen ny ren  or rho associated coiled coil containing protein kinase  or p rock  or rock or ec   pipeline review h  summary rho associated protein kinase  renal carcinoma antigen ny ren  or rho associated coiled coil containing protein kinase  or p rock  or rock or ec   rhoassociated protein kinase  rock is a protein serinethreonine kinase it is a key regulator of actin cytoskeleton and read more serinethreonine protein kinase a raf proto oncogene a raf or proto oncogene pks or araf or ec   pipeline review h  jul  global markets direct  pages    code  mrs   serinethreonine protein kinase a raf proto oncogene a raf or proto oncogene pks or araf or ec   pipeline review h  summary serinethreonine protein kinase a raf proto oncogene a raf or proto oncogene pks or araf or ec  pipeline target constitutes close to  molecules out of which approximately  molecules are developed by companies the latest report serinethreonine protein kinase a raf  pipeline review h  outlays comprehensive information on the serin read more map kinase interacting serinethreonine protein kinase  map kinase signal integrating kinase  or mknk or ec   pipeline review h  jul  global markets direct  pages    code  mrs   map kinase interacting serinethreonine protein kinase  map kinase signal integrating kinase  or mknk or ec   pipeline review h  summary according to the recently published report map kinase interacting serinethreonine protein kinase   pipeline review h  map kinase interacting serinethreonine protein kinase  map kinase signal integrating kinase  or mknk or ec  pipeline target constitutes close to  molecules out of which approximately  molecu read more interleukin  receptor associated kinase  renal carcinoma antigen ny ren  or irak or ec   pipeline review h  jul  global markets direct  pages    code  mrs   interleukin  receptor associated kinase  renal carcinoma antigen ny ren  or irak or ec   pipeline review h  summary interleukin  receptor associated kinase  renal carcinoma antigen ny ren  or irak or ec   interleukin receptorassociated kinase  irak is a protein kinase involved in signaling innate immune responses from tolllike receptors mutations in irak result in irak deficiency and recurrent invasive pneumococcal disease it phosphoryla read more mitogen activated protein kinase  c jun n terminal kinase  or jnk  or stress activated protein kinase jnk or stress activated protein kinase c or mapk or ec   pipeline review h  jul  global markets direct  pages    code  mrs   mitogen activated protein kinase  c jun n terminal kinase  or jnk  or stress activated protein kinase jnk or stress activated protein kinase c or mapk or ec   pipeline review h  summary mitogen activated protein kinase  c jun n terminal kinase  or jnk  or stress activated protein kinase jnk or stress activated protein kinase c or mapk or ec  pipeline target constitutes close to  molecules out of which approximately  molecules are developed by read more protein glutamine gamma glutamyltransferase  tissue transglutaminase or transglutaminase c or transglutaminase h or transglutaminase  or tgase c or tgase h or tgm or ec   pipeline review h  jul  global markets direct  pages    code  mrs   protein glutamine gamma glutamyltransferase  tissue transglutaminase or transglutaminase c or transglutaminase h or transglutaminase  or tgase c or tgase h or tgm or ec   pipeline review h  summary according to the recently published report protein glutamine gamma glutamyltransferase   pipeline review h  protein glutamine gamma glutamyltransferase  tissue transglutaminase or transglutaminase c or transglutaminase h or transglutaminase  or tgase c or tgase read more payment mode single user  usd multi user  usd corporate user  usd latest report  global nonslip epoxy glass flake paint market research report  global parking sensors market research report  global nitrogen oxide sensor market research report  global nuclear density gauge market research report  global automotive interior materials market research report view more latest news global chitosan market set for rapid growth to reach usd  billion by  zion market research has published a new report titled chitosan market for water treatment biomed development of ecommerce to reshape global mobile hotspot router market mobile hotspot is a popular feature on smart phones that provide wireless internet access on many global carotenoids market is expected to reach around usd  billion in  zion market research has published a new report titled carotenoids market by type astaxanthin be soaring demand from food  beverages industry to act as prime driving for ascorbic acid market reports zion market research ascorbic acid is extensively available in nature mostly rich in leafy vegetables and fresh fruits global energy management system ems market is set for a rapid growth and is expected to reach usd  million by  zion market research has published a new report titled energy management system market ems by so view more single user  usd view pricing find help how to order disclaimer faqs return policy sitemap our company about us terms and conditions privacy policy we accept the following payment methods     market research store  market research reports amicus therapeutics inc  product pipeline review   infomarketreportscentercom  us x login sign up facebook twitter linkedin google  mrc blog youtube amicus therapeutics inc  product pipeline review   home  pharmaceuticals  global markets direct  amicus therapeutics inc  product pipeline review   report details amicus therapeutics inc  product pipeline review   sku gmdaug category pharmaceuticals publisher global markets direct pages  published jul skugmdaug categorypharmaceuticals publisherglobal markets direct pages published onjul request discount pay by wireinvoice description table of content list of figures request sample description amicus therapeutics inc  product pipeline review   summary global markets directs amicus therapeutics inc  product pipeline review   provides an overview of the amicus therapeutics incs pharmaceutical research and development focus this report provides comprehensive information on the current therapeutic developmental pipeline of amicus therapeutics incs complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projects global markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets directs team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass products note certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease scope  the report provides brief overview of amicus therapeutics inc including business description key information and facts and its locations and subsidiaries  the report reviews current pipeline of amicus therapeutics incs human therapeutic division and enlists all their major and minor projects  the report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones  special feature on outlicensed and partnered product portfolio  the report summarizes all the dormant and discontinued pipeline projects  latest company statement  latest news and deals relating to the amicus therapeutics incs pipeline products reasons to buy  evaluate amicus therapeutics incs strategic position with total access to detailed information on its product pipeline  assess the growth potential of amicus therapeutics inc in its therapy areas of focus  identify new drug targets and therapeutic classes in the amicus therapeutics incs rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas  exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps  develop strategic initiatives by understanding the focus areas of amicus therapeutics inc and exploit collaboration and partnership opportunities  identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage  plan mergers and acquisitions effectively by identifying the most promising pipeline of amicus therapeutics inc  develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope  explore the dormant and discontinued projects of amicus therapeutics inc and identify potential opportunities in those areas  avoid intellectual property rights related issues newspress release precision medicine how the life science industry can improve outcomes through to achieve successful precision medicine at scale and to be able to offer it as an everyday treatment option researchers in drug rd need to better understand and manage the reams of unstructured datread more regenerative medicine market to hit  billion by  the current regenerative medicine market is worth  billion globally and will hit over  billion by  as impact of trump administrationread more  benefits of microneedlingmicroneedling hundreds of tiny pin pricks going into your skin might sound weird but it could just be the best thing that ever happened to your faceread more table of content table of contents table of contents  list of tables  list of figures  amicus therapeutics inc snapshot  amicus therapeutics inc overview  key information  key facts  amicus therapeutics inc  research and development overview  key therapeutic areas  amicus therapeutics inc  pipeline review  pipeline products by stage of development  pipeline products  monotherapy  pipeline products  combination treatment modalities  pipeline products  partnered products  partnered productscombination treatment modalities  amicus therapeutics inc  pipeline products glance  amicus therapeutics inc  late stage pipeline products  preregistration productscombination treatment modalities  phase iii productscombination treatment modalities  amicus therapeutics inc  clinical stage pipeline products  phase ii productscombination treatment modalities  amicus therapeutics inc  early stage pipeline products  preclinical productscombination treatment modalities  amicus therapeutics inc  drug profiles  migalastat hydrochloride  product description  mechanism of action  rd progress  migalastat hydrochloride  agalsidase alfa  product description  mechanism of action  rd progress  duvoglustat hydrochloride  alglucosidase alfa  product description  mechanism of action  rd progress  duvoglustat hydrochloride  atb  product description  mechanism of action  rd progress  afegostat tartrate  product description  mechanism of action  rd progress  afegostat tartrate  ert  product description  mechanism of action  rd progress  at  product description  mechanism of action  rd progress  atb  product description  mechanism of action  rd progress  chaperoneert combinations  product description  mechanism of action  rd progress  laronidase  chaperone  product description  mechanism of action  rd progress  migalastat hydrochloride  enzyme replacement therapy biobetter  product description  mechanism of action  rd progress  recombinant enzyme for lysosomal storage disorder  product description  mechanism of action  rd progress  small molecule for neurodegenerative diseases  product description  mechanism of action  rd progress  amicus therapeutics inc  pipeline analysis  amicus therapeutics inc  pipeline products by target  amicus therapeutics inc  pipeline products by route of administration  amicus therapeutics inc  pipeline products by molecule type  amicus therapeutics inc  pipeline products by mechanism of action  amicus therapeutics inc  recent pipeline updates  amicus therapeutics inc  dormant projects  amicus therapeutics inc  company statement  amicus therapeutics inc  locations and subsidiaries  head office  other locations  subsidiaries  appendix  methodology  coverage  secondary research  primary research  expert panel validation  contact us  disclaimer  list of figures list of tables amicus therapeutics inc key information  amicus therapeutics inc key facts  amicus therapeutics inc  pipeline by indication   amicus therapeutics inc  pipeline by stage of development   amicus therapeutics inc  monotherapy products in pipeline   amicus therapeutics inc  combination treatment modalities in pipeline   amicus therapeutics inc  partnered products in pipeline   amicus therapeutics inc  partnered products combination treatment modalities   amicus therapeutics inc  preregistration   amicus therapeutics inc  phase iii   amicus therapeutics inc  phase ii   amicus therapeutics inc  preclinical   amicus therapeutics inc  pipeline by target   amicus therapeutics inc  pipeline by route of administration   amicus therapeutics inc  pipeline by molecule type   amicus therapeutics inc  pipeline products by mechanism of action   amicus therapeutics inc  recent pipeline updates   amicus therapeutics inc  dormant developmental projects  amicus therapeutics inc subsidiaries  list of figures amicus therapeutics inc  pipeline by top  indication   amicus therapeutics inc  pipeline by stage of development   amicus therapeutics inc  monotherapy products in pipeline   amicus therapeutics inc  combination treatment modalities in pipeline   amicus therapeutics inc  pipeline by top  target   amicus therapeutics inc  pipeline by top  route of administration   amicus therapeutics inc  pipeline by top  molecule type   amicus therapeutics inc  pipeline products by top  mechanism of action   please select license type single user electronic pdf   site user electronic pdf   enterprise wide electronic pdf   add to cart buy now related reports global oncology market to   robust growth driven by rising prevalence and increased uptake of immune checkpoint inhibitors urinary incontinence  pipeline review h  ict investment trends in china enterprises initiatives inclined towards digitization fuelling ict investments global pain therapeutics market to   innovative new products to address unmet need within chronic pain and migraine and tackle opioid abuse global veterinary therapeutics market research report  request sample mr mrs ms dr afghanistan  albania  algeria  andorra  angola  antigua and barbuda  argentina  armenia  australia  austria  azerbaijan  bahamas the  bahrain  bangladesh  barbados  belarus  belgium  belize  benin  bhutan  bolivia  bosnia and herzegovina  botswana  brazil  brunei  bulgaria  burkina faso  burundi  cambodia  cameroon  canada  cape verde  central african republic  chad  chile  china peoples republic of  colombia  comoros  congo congo  kinshasa  congo congo  brazzaville  costa rica  cote divoire ivory coast  croatia  cuba  cyprus  czech republic  denmark  djibouti  dominica  dominican republic  and  ecuador  egypt  el salvador  equatorial guinea  eritrea  estonia  ethiopia  fiji  finland  france  gabon  gambia the  georgia  germany  ghana  greece  grenada  guatemala  guinea  guineabissau  guyana  haiti  honduras  hungary  iceland  india  indonesia  iran  iraq  ireland  israel  italy  jamaica  japan  jordan  kazakhstan  kenya  kiribati  korea north  korea south  kuwait  kyrgyzstan  laos  latvia  lebanon  lesotho  liberia  libya  liechtenstein  lithuania  luxembourg  macedonia  madagascar  malawi  malaysia  maldives  mali  malta  marshall islands  mauritania  mauritius  mexico  micronesia  moldova  monaco  mongolia  montenegro  morocco  mozambique  myanmar burma  namibia  nauru  nepal  netherlands  new zealand  nicaragua  niger  nigeria  norway  oman  pakistan  palau  panama  papua new guinea  paraguay  peru  philippines  poland  portugal  qatar  romania  russia  rwanda  saint kitts and nevis  saint lucia  saint vincent and the grenadines  samoa  san marino  sao tome and principe  saudi arabia  senegal  serbia  seychelles  sierra leone  singapore  slovakia  slovenia  solomon islands  somalia  south africa  spain  sri lanka  sudan  suriname  swaziland  sweden  switzerland  syria  tajikistan  tanzania  thailand  timorleste east timor  togo  tonga  trinidad and tobago  tunisia  turkey  turkmenistan  tuvalu  uganda  ukraine  united arab emirates  united kingdom  united states  uruguay  uzbekistan  vanuatu  vatican city  venezuela  vietnam  yemen  zambia  zimbabwe  abkhazia  china republic of taiwan  nagornokarabakh  northern cyprus  pridnestrovie transnistria  somaliland  south ossetia  ashmore and cartier islands  christmas island  cocos keeling islands  coral sea islands  heard island and mcdonald islands  norfolk island  new caledonia  french polynesia  mayotte  saint barthelemy  saint martin  saint pierre and miquelon  wallis and futuna  french southern and antarctic lands  clipperton island  bouvet island  cook islands  niue  tokelau  guernsey  isle of man  jersey  anguilla  bermuda  british indian ocean territory  british sovereign base areas  british virgin islands  cayman islands  falkland islands islas malvinas  gibraltar  montserrat  pitcairn islands  saint helena  south georgia  south sandwich islands  turks and caicos islands  northern mariana islands  puerto rico  and  american samoa  baker island  guam  howland island  jarvis island  johnston atoll  kingman reef  midway islands  navassa island  palmyra atoll  us virgin islands  wake island  hong kong  macau  faroe islands  greenland  french guiana  guadeloupe  martinique  reunion  aland  aruba  netherlands antilles  svalbard  ascension  tristan da cunha  australian antarctic territory  ross dependency  peter i island  queen maud land  british antarctic territory  send request discount mr mrs ms dr afghanistan  albania  algeria  andorra  angola  antigua and barbuda  argentina  armenia  australia  austria  azerbaijan  bahamas the  bahrain  bangladesh  barbados  belarus  belgium  belize  benin  bhutan  bolivia  bosnia and herzegovina  botswana  brazil  brunei  bulgaria  burkina faso  burundi  cambodia  cameroon  canada  cape verde  central african republic  chad  chile  china peoples republic of  colombia  comoros  congo congo  kinshasa  congo congo  brazzaville  costa rica  cote divoire ivory coast  croatia  cuba  cyprus  czech republic  denmark  djibouti  dominica  dominican republic  and  ecuador  egypt  el salvador  equatorial guinea  eritrea  estonia  ethiopia  fiji  finland  france  gabon  gambia the  georgia  germany  ghana  greece  grenada  guatemala  guinea  guineabissau  guyana  haiti  honduras  hungary  iceland  india  indonesia  iran  iraq  ireland  israel  italy  jamaica  japan  jordan  kazakhstan  kenya  kiribati  korea north  korea south  kuwait  kyrgyzstan  laos  latvia  lebanon  lesotho  liberia  libya  liechtenstein  lithuania  luxembourg  macedonia  madagascar  malawi  malaysia  maldives  mali  malta  marshall islands  mauritania  mauritius  mexico  micronesia  moldova  monaco  mongolia  montenegro  morocco  mozambique  myanmar burma  namibia  nauru  nepal  netherlands  new zealand  nicaragua  niger  nigeria  norway  oman  pakistan  palau  panama  papua new guinea  paraguay  peru  philippines  poland  portugal  qatar  romania  russia  rwanda  saint kitts and nevis  saint lucia  saint vincent and the grenadines  samoa  san marino  sao tome and principe  saudi arabia  senegal  serbia  seychelles  sierra leone  singapore  slovakia  slovenia  solomon islands  somalia  south africa  spain  sri lanka  sudan  suriname  swaziland  sweden  switzerland  syria  tajikistan  tanzania  thailand  timorleste east timor  togo  tonga  trinidad and tobago  tunisia  turkey  turkmenistan  tuvalu  uganda  ukraine  united arab emirates  united kingdom  united states  uruguay  uzbekistan  vanuatu  vatican city  venezuela  vietnam  yemen  zambia  zimbabwe  abkhazia  china republic of taiwan  nagornokarabakh  northern cyprus  pridnestrovie transnistria  somaliland  south ossetia  ashmore and cartier islands  christmas island  cocos keeling islands  coral sea islands  heard island and mcdonald islands  norfolk island  new caledonia  french polynesia  mayotte  saint barthelemy  saint martin  saint pierre and miquelon  wallis and futuna  french southern and antarctic lands  clipperton island  bouvet island  cook islands  niue  tokelau  guernsey  isle of man  jersey  anguilla  bermuda  british indian ocean territory  british sovereign base areas  british virgin islands  cayman islands  falkland islands islas malvinas  gibraltar  montserrat  pitcairn islands  saint helena  south georgia  south sandwich islands  turks and caicos islands  northern mariana islands  puerto rico  and  american samoa  baker island  guam  howland island  jarvis island  johnston atoll  kingman reef  midway islands  navassa island  palmyra atoll  us virgin islands  wake island  hong kong  macau  faroe islands  greenland  french guiana  guadeloupe  martinique  reunion  aland  aruba  netherlands antilles  svalbard  ascension  tristan da cunha  australian antarctic territory  ross dependency  peter i island  queen maud land  british antarctic territory  send pay by wireinvoice mr mrs ms dr afghanistan  albania  algeria  andorra  angola  antigua and barbuda  argentina  armenia  australia  austria  azerbaijan  bahamas the  bahrain  bangladesh  barbados  belarus  belgium  belize  benin  bhutan  bolivia  bosnia and herzegovina  botswana  brazil  brunei  bulgaria  burkina faso  burundi  cambodia  cameroon  canada  cape verde  central african republic  chad  chile  china peoples republic of  colombia  comoros  congo congo  kinshasa  congo congo  brazzaville  costa rica  cote divoire ivory coast  croatia  cuba  cyprus  czech republic  denmark  djibouti  dominica  dominican republic  and  ecuador  egypt  el salvador  equatorial guinea  eritrea  estonia  ethiopia  fiji  finland  france  gabon  gambia the  georgia  germany  ghana  greece  grenada  guatemala  guinea  guineabissau  guyana  haiti  honduras  hungary  iceland  india  indonesia  iran  iraq  ireland  israel  italy  jamaica  japan  jordan  kazakhstan  kenya  kiribati  korea north  korea south  kuwait  kyrgyzstan  laos  latvia  lebanon  lesotho  liberia  libya  liechtenstein  lithuania  luxembourg  macedonia  madagascar  malawi  malaysia  maldives  mali  malta  marshall islands  mauritania  mauritius  mexico  micronesia  moldova  monaco  mongolia  montenegro  morocco  mozambique  myanmar burma  namibia  nauru  nepal  netherlands  new zealand  nicaragua  niger  nigeria  norway  oman  pakistan  palau  panama  papua new guinea  paraguay  peru  philippines  poland  portugal  qatar  romania  russia  rwanda  saint kitts and nevis  saint lucia  saint vincent and the grenadines  samoa  san marino  sao tome and principe  saudi arabia  senegal  serbia  seychelles  sierra leone  singapore  slovakia  slovenia  solomon islands  somalia  south africa  spain  sri lanka  sudan  suriname  swaziland  sweden  switzerland  syria  tajikistan  tanzania  thailand  timorleste east timor  togo  tonga  trinidad and tobago  tunisia  turkey  turkmenistan  tuvalu  uganda  ukraine  united arab emirates  united kingdom  united states  uruguay  uzbekistan  vanuatu  vatican city  venezuela  vietnam  yemen  zambia  zimbabwe  abkhazia  china republic of taiwan  nagornokarabakh  northern cyprus  pridnestrovie transnistria  somaliland  south ossetia  ashmore and cartier islands  christmas island  cocos keeling islands  coral sea islands  heard island and mcdonald islands  norfolk island  new caledonia  french polynesia  mayotte  saint barthelemy  saint martin  saint pierre and miquelon  wallis and futuna  french southern and antarctic lands  clipperton island  bouvet island  cook islands  niue  tokelau  guernsey  isle of man  jersey  anguilla  bermuda  british indian ocean territory  british sovereign base areas  british virgin islands  cayman islands  falkland islands islas malvinas  gibraltar  montserrat  pitcairn islands  saint helena  south georgia  south sandwich islands  turks and caicos islands  northern mariana islands  puerto rico  and  american samoa  baker island  guam  howland island  jarvis island  johnston atoll  kingman reef  midway islands  navassa island  palmyra atoll  us virgin islands  wake island  hong kong  macau  faroe islands  greenland  french guiana  guadeloupe  martinique  reunion  aland  aruba  netherlands antilles  svalbard  ascension  tristan da cunha  australian antarctic territory  ross dependency  peter i island  queen maud land  british antarctic territory  single user electronic pdf site user electronic pdf enterprise wide electronic pdf cd rom hard copy send request quote mr mrs ms dr afghanistan  albania  algeria  andorra  angola  antigua and barbuda  argentina  armenia  australia  austria  azerbaijan  bahamas the  bahrain  bangladesh  barbados  belarus  belgium  belize  benin  bhutan  bolivia  bosnia and herzegovina  botswana  brazil  brunei  bulgaria  burkina faso  burundi  cambodia  cameroon  canada  cape verde  central african republic  chad  chile  china peoples republic of  colombia  comoros  congo congo  kinshasa  congo congo  brazzaville  costa rica  cote divoire ivory coast  croatia  cuba  cyprus  czech republic  denmark  djibouti  dominica  dominican republic  and  ecuador  egypt  el salvador  equatorial guinea  eritrea  estonia  ethiopia  fiji  finland  france  gabon  gambia the  georgia  germany  ghana  greece  grenada  guatemala  guinea  guineabissau  guyana  haiti  honduras  hungary  iceland  india  indonesia  iran  iraq  ireland  israel  italy  jamaica  japan  jordan  kazakhstan  kenya  kiribati  korea north  korea south  kuwait  kyrgyzstan  laos  latvia  lebanon  lesotho  liberia  libya  liechtenstein  lithuania  luxembourg  macedonia  madagascar  malawi  malaysia  maldives  mali  malta  marshall islands  mauritania  mauritius  mexico  micronesia  moldova  monaco  mongolia  montenegro  morocco  mozambique  myanmar burma  namibia  nauru  nepal  netherlands  new zealand  nicaragua  niger  nigeria  norway  oman  pakistan  palau  panama  papua new guinea  paraguay  peru  philippines  poland  portugal  qatar  romania  russia  rwanda  saint kitts and nevis  saint lucia  saint vincent and the grenadines  samoa  san marino  sao tome and principe  saudi arabia  senegal  serbia  seychelles  sierra leone  singapore  slovakia  slovenia  solomon islands  somalia  south africa  spain  sri lanka  sudan  suriname  swaziland  sweden  switzerland  syria  tajikistan  tanzania  thailand  timorleste east timor  togo  tonga  trinidad and tobago  tunisia  turkey  turkmenistan  tuvalu  uganda  ukraine  united arab emirates  united kingdom  united states  uruguay  uzbekistan  vanuatu  vatican city  venezuela  vietnam  yemen  zambia  zimbabwe  abkhazia  china republic of taiwan  nagornokarabakh  northern cyprus  pridnestrovie transnistria  somaliland  south ossetia  ashmore and cartier islands  christmas island  cocos keeling islands  coral sea islands  heard island and mcdonald islands  norfolk island  new caledonia  french polynesia  mayotte  saint barthelemy  saint martin  saint pierre and miquelon  wallis and futuna  french southern and antarctic lands  clipperton island  bouvet island  cook islands  niue  tokelau  guernsey  isle of man  jersey  anguilla  bermuda  british indian ocean territory  british sovereign base areas  british virgin islands  cayman islands  falkland islands islas malvinas  gibraltar  montserrat  pitcairn islands  saint helena  south georgia  south sandwich islands  turks and caicos islands  northern mariana islands  puerto rico  and  american samoa  baker island  guam  howland island  jarvis island  johnston atoll  kingman reef  midway islands  navassa island  palmyra atoll  us virgin islands  wake island  hong kong  macau  faroe islands  greenland  french guiana  guadeloupe  martinique  reunion  aland  aruba  netherlands antilles  svalbard  ascension  tristan da cunha  australian antarctic territory  ross dependency  peter i island  queen maud land  british antarctic territory  send market reports center  copyright  all rights reserved amicus therapeutics inc  product pipeline review    reportsnreports market research report welcome guest    registerlogin   contact us   about us      advanced search home ›  pharmaceuticals ›  report detail amicus therapeutics inc  product pipeline review   published may  no of pages  price  single user license us   corporate user license us     report description table of contents inquire before buying global markets directs amicus therapeutics inc product pipeline review  provides an overview of the amicus therapeutics incs pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of amicus therapeutics incs complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsglobal markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets directs team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasescopethe report provides brief overview of amicus therapeutics inc including business description key information and facts and its locations and subsidiariesthe report reviews current pipeline of amicus therapeutics incs human therapeutic division and enlists all their major and minor projectsthe report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestonesspecial feature on outlicensed and partnered product portfoliothe report summarizes all the dormant and discontinued pipeline projectslatest company statementlatest news and deals relating to the amicus therapeutics incs pipeline productsreasons to buyevaluate amicus therapeutics incs strategic position with total access to detailed information on its product pipelineassess the growth potential of amicus therapeutics inc in its therapy areas of focusidentify new drug targets and therapeutic classes in the amicus therapeutics incs rd portfolio and develop key strategic initiatives to reinforce pipeline in those areasexploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gapsdevelop strategic initiatives by understanding the focus areas of amicus therapeutics inc and exploit collaboration and partnership opportunitiesidentify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantageplan mergers and acquisitions effectively by identifying the most promising pipeline of amicus therapeutics incdevelop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scopeexplore the dormant and discontinued projects of amicus therapeutics inc and identify potential opportunities in those areasavoid intellectual property rights related issues amicus therapeutics inc  product pipeline review   table of contentstable of contents list of tables list of figures amicus therapeutics inc snapshot amicus therapeutics inc overview key information key facts amicus therapeutics inc  research and development overview key therapeutic areas amicus therapeutics inc  pipeline review pipeline products by stage of development pipeline products  monotherapy pipeline products  combination treatment modalities pipeline products  partnered products partnered productscombination treatment modalities amicus therapeutics inc  pipeline products glance amicus therapeutics inc  late stage pipeline products phase iii productscombination treatment modalities amicus therapeutics inc  clinical stage pipeline products phase ii productscombination treatment modalities phase i productscombination treatment modalities amicus therapeutics inc  early stage pipeline products preclinical productscombination treatment modalities discovery productscombination treatment modalities amicus therapeutics inc  drug profiles migalastat hydrochloride product description mechanism of action rd progress afegostat tartrate product description mechanism of action rd progress duvoglustat hydrochloride  alglucosidase alfa product description mechanism of action rd progress migalastat hydrochloride  enzyme replacement therapy product description mechanism of action rd progress migalastat hydrochloride  agalsidase alfa product description mechanism of action rd progress at product description mechanism of action rd progress atb  chaperone product description mechanism of action rd progress chaperoneert combinations product description mechanism of action rd progress laronidase  chaperone product description mechanism of action rd progress recombinant enzyme for lysosomal storage disorder product description mechanism of action rd progress recombinant enzyme for gaucher disease product description mechanism of action rd progress amicus therapeutics inc  pipeline analysis amicus therapeutics inc  pipeline products by target amicus therapeutics inc  pipeline products by route of administration amicus therapeutics inc  pipeline products by molecule type amicus therapeutics inc  pipeline products by mechanism of action amicus therapeutics inc  recent pipeline updates amicus therapeutics inc  dormant projects amicus therapeutics inc  company statement amicus therapeutics inc  locations and subsidiaries head office other locations  subsidiaries appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tablesamicus therapeutics inc key information amicus therapeutics inc key facts amicus therapeutics inc  pipeline by indication  amicus therapeutics inc  pipeline by stage of development  amicus therapeutics inc  monotherapy products in pipeline  amicus therapeutics inc  combination treatment modalities in pipeline  amicus therapeutics inc  partnered products in pipeline  amicus therapeutics inc  partnered products combination treatment modalities  amicus therapeutics inc  phase iii  amicus therapeutics inc  phase ii  amicus therapeutics inc  phase i  amicus therapeutics inc  preclinical  amicus therapeutics inc  discovery  amicus therapeutics inc  pipeline by target  amicus therapeutics inc  pipeline by route of administration  amicus therapeutics inc  pipeline by molecule type  amicus therapeutics inc  pipeline products by mechanism of action  amicus therapeutics inc  recent pipeline updates  amicus therapeutics inc  dormant developmental projects amicus therapeutics inc subsidiaries list of figuresamicus therapeutics inc  pipeline by top  indication  amicus therapeutics inc  pipeline by stage of development  amicus therapeutics inc  monotherapy products in pipeline  amicus therapeutics inc  combination treatment modalities in pipeline  amicus therapeutics inc  pipeline by top  target  amicus therapeutics inc  pipeline by top  route of administration  amicus therapeutics inc  pipeline by top  molecule type  amicus therapeutics inc  pipeline products by top  mechanism of action   published by global markets direct product code global markets direct did you find what you arewere looking for  if not read below and browse through other relevant pages for similar market research reports or get in touch with us through the formcontact info in your right navigation panel and well share relevant market report titles for you to explore related reports global onychomycosis tinea unguium drug detailed analysis report  this report splits onychomycosis tinea unguium drug by product drug form by product usage type this shares the history data information from  to  and forecast from  to  and this report mainly introduces volume and value marke  united states vaginal pessary market report status and outlook this report will be delivered in  business days after the order is placed the vaginal pessary market size will be xx million usd in  in united states from the xx million usd in  with a cagr compound annual growth rate xx fro  united states tuberculin market report status and outlook this report will be delivered in  business days after the order is placed the tuberculin market size will be xx million usd in  in united states from the xx million usd in  with a cagr compound annual growth rate xx from   philippines vaginal pessary market report status and outlook this report will be delivered in  business days after the order is placed the vaginal pessary market size will be xx million usd in  in philippines from the xx million usd in  with a cagr compound annual growth rate xx from   philippines tuberculin market report status and outlook this report will be delivered in  business days after the order is placed the tuberculin market size will be xx million usd in  in philippines from the xx million usd in  with a cagr compound annual growth rate xx from    malaysia vaginal pessary market report status and outlook this report will be delivered in  business days after the order is placed the vaginal pessary market size will be xx million usd in  in malaysia from the xx million usd in  with a cagr compound annual growth rate xx from   malaysia tuberculin market report status and outlook this report will be delivered in  business days after the order is placed the tuberculin market size will be xx million usd in  in malaysia from the xx million usd in  with a cagr compound annual growth rate xx from  to   japan vaginal pessary market report status and outlook this report will be delivered in  business days after the order is placed the vaginal pessary market size will be xx million usd in  in japan from the xx million usd in  with a cagr compound annual growth rate xx from  t  japan tuberculin market report status and outlook this report will be delivered in  business days after the order is placed the tuberculin market size will be xx million usd in  in japan from the xx million usd in  with a cagr compound annual growth rate xx from  to   india vaginal pessary market report status and outlook this report will be delivered in  business days after the order is placed the vaginal pessary market size will be xx million usd in  in india from the xx million usd in  with a cagr compound annual growth rate xx from  t why reportsnreportscom  market research reports and growing top fortune  organizations trust us for research data  support on call as well as emails your details are safe with us free support for your research requirements report delivery email delivery time upto  hrs  working days upto  hrs max  weekends and public holidays research support  custom research if this business study does not have the data and information analysis you need contact us with your research requirements we explore available market research reports to map your needs and share report titles with you alternatively we can also offer custom research that suits your budget and timelines share your information requirements here connect with us email salesreportsandreportscom call       home category publisher country latest reports markets discounted reports upcoming reports contact us subscription option using our subscription option you get access to market research reports and industry data of consumer goods market as per your needs get the best of consumer goods research reports by utilizing your research budgets in an optimum way more about our subscription option report alerts get email alerts about market research reports from industries and publishers of your interest please enter a valid email id thank you you have successfully subscribed to our report alerts avail upto  discount on below publisher reports technavio azoth analytics   reportsnreports all rights reserved disclamer privacy policy  terms and conditions  our market research blog  sitemap feeds rss  latest reports sales growth analysis amicus therapeutics inc fold avon products inc avp  usa commerce daily ecommerce news wall street technology economy search home about us our team contact us sign in welcome log into your account your username your password forgot your password get help password recovery recover your password your email a password will be emailed to you usa commerce daily ecommerce news wall street technology economy home ecommerce news sales growth analysis amicus therapeutics inc fold avon products inc avp ecommerce news sales growth analysis amicus therapeutics inc fold avon products inc avp by luis castro  july   share on facebook tweet on twitter shares of amicus therapeutics inc nasdaqfold are making a strong comeback as they have jumped  since bottoming out at  on dec   thanks to a rise of almost  in the past five days the stock price is now up  so far on the year — still in strong territory in this case shares are down  from   the week high touched on jul   and are keeping their losses at  for the past  months fold target price reaches  brokerage houses on average are recommending investors to buy amicus therapeutics inc fold’s shares projecting a  target price analysts‟ target price forecasts are a prediction of a stock‟s future price generally over the  months following the release date asquith et al  this forecast is a point estimate that provides investors with a benchmark against which to directly compare stock price in the short runtarget prices made by analysts employed by large brokers who have access to a greater resource pool are more likely to be met over the month forecast period how quickly amicus therapeutics inc fold’s sales declined fold’s revenue has declined at an average annualized rate of about  during the past five years however the company’s most recent quarter decrease of  looks unattractive the sales growth rate for a stock is a measure of how the stock’s sales per share sps has grown over a specific period of time it tells an investor how quickly a company is increasing its revenues the sales growth rate helps investors determine how strong the overall growthorientation is for a stock or portfolio avon products inc achieves belowaverage profit margin the best measure of a company is its profitability for without it it cannot grow and if it doesn’t grow then its stock will trend downward increasing profits are the best indication that a company can pay dividends and that the share price will trend upward creditors will loan money at a cheaper rate to a profitable company than to an unprofitable one consequently profitable companies can use leverage to increase stockholders’ equity even more profitability ratios compare different accounts to see how efficiently a business is generating profits these ratios show how well income is generated through operations and are important to both creditors and investors they help determine the company’s ability to continue operating currently amicus therapeutics inc net profit margin for the  months is at  comparatively the peers have a net margin  and the sector’s average is  in that light it seems in weak position compared to its peers and sector the profit margin measures the amount of net income earned with each dollar’s worth of revenue it shows the percentage of sales that remain after all of the company’s expenses have been paid the higher the ratio the better avon products inc nyseavp is another stock that is grabbing investors attention these days its shares have trimmed  since hitting a peak level of  on oct   meanwhile due to a recent pullback which led to a fall of almost  in the past one month the stock price is now with underperforming  so far on the year — still in weak zone in this case shares are  higher from  the worst price in  weeks suffered on may   but are collecting gains at  for the past six months analysts see avon products inc  above current levels the good news is there’s still room for avon products inc avp to grow at recent closing price of  avp has a chance to add  or  in  weeks based on mean target price  placed by analyststhe analyst consensus opinion of  looks like a hold it has a month beta of   so you might be in for a bumpy ride are avon products inc nyseavp earnings growing rapidly for the past  years avon products inc’s eps growth has been nearly  sure the percentage is discouraging but better times are ahead as looking out over a next year period analysts expect the company to see its earnings go up by  annually is avp turning profits into returns avon products inc avp’s roe is  while industry’s is  the average roe for the sector stands at  the return on equity roe also known as return on investment roi is the best measure of the return since it is the product of the operating performance asset turnover and debtequity management of the firm if a firm can borrow money and use it to achieve a higher return than the cost of the debt then the leveraging creates additional revenue that accrues to stockholders as increased equity avon products inc’s roa is  while industry’s average is  as with any return the higher this number the better however it too needs to be taken into the context of a company’s peer group as well as its sector the average return on assets for companies in the same sector is  the return on assets roa aka return on total assets return on average assets is one of the most widely used profitability ratios because it is related to both profit margin and asset turnover and shows the rate of return for both creditors and investors of the company roa shows how well a company controls its costs and utilizes its resources popular posts the cocacola company ko stock technicals are in the neutral area july   if you lack direction on whole foods market inc wfm you july   are jpmorgan chase  co jpm stock technicals favorable july   technical clues for altria group inc mo investors july   usa commerce daily knows how managing information determines success in the modern world people who are really looking for information about business companies and latest stock news – usa commerce daily is the right place usa commerce daily does not gather only pleasant news it covers everything that is really important this paper still provides own investigations on the high level local and international events are given with careful and complete analysis usa commerce daily is here to grab all the latest – hottest news and popular interview and bring them to you in a concise way categories business ecommerce news economy technology wall street recent posts the cocacola company ko stock technicals are in the neutral area if you lack direction on whole foods market inc wfm you need to read this are jpmorgan chase  co jpm stock technicals favorable technical clues for altria group inc mo investors exxon mobil corporation xom technicals are painting a bleak picture home about us our team contact us copyright  by usa commerce daily amicus therapeutics inc nasdaqfold quotes  news  google financecookies help us deliver our services by using our services you agree to our use of cookieslearn moregot itmy accountsearchmapsyoutubeplaynewsgmaildrivecalendargoogletranslatephotosmoreshoppingwalletfinancedocsbooksbloggercontactshangoutskeepeven more from googlesign inhidden fieldssearch financeadobe flash player is required for interactive charts allowfinanceamicus therapeutics incnasdaqfoldadd to portfoliocompanysummarynewsoption chainrelated companieshistorical pricesfinancialsmarketsnewsportfoliosstock screenergoogle domestic trendsrecent quotes  daysyou have no recent quoteschg   amicus therapeutics inc  public nasdaqfold   watch this stock      jul   close nasdaq realtime data  disclaimer currency in usd range     week    open  vol  avg m mkt cap b pe      divyield      eps  shares m beta  inst own  news relevance date all news for amicus therapeutics inc » subscribe advertisement events add fold to my calendars aug   q  amicus therapeutics inc earnings release estimated  am edt  jul   amicus therapeutics inc conference call to discuss its amicus therapeutics us pathway and upcoming nda submission for migalastat  jun   amicus therapeutics inc at goldman sachs global healthcare conference  jun   amicus therapeutics inc annual shareholders meeting jun   amicus therapeutics inc annual shareholders meeting estimated may   amicus therapeutics inc at ubs global healthcare conference  may   amicus therapeutics inc at bank of america merrill lynch healthcare conference  may   amicus therapeutics inc conference call to update on positive functional data from initial patients in pompe phase  study  may   q  amicus therapeutics inc earnings release may   q  amicus therapeutics inc earnings call  more events from dailyfinance »     key stats and ratios q mar   net profit margin   operating margin   ebitd margin   return on average assets   return on average equity   employees   cdp score   screen stocks with similar metrics » address  cedarbrook drcranbury nj united states  map phone fax website links httpwwwamicusrxcom external links analyst estimates  marketwatch sec filings  edgar online major holders  msn money research reports  reuters settings  technicals  link to this view volume delayed by  minsprices are not from all markets sources include six advertisement related companies show most recent quarter most recent annual add or remove columns save changes cancel sector healthcare  industry pharmaceuticals  nec more from factset » description amicus therapeutics inc is a biotechnology company the company is engaged in the discovery development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases its lead product migalastat hcl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy ert for fabry disease its pipeline also includes sd which is a product candidate in latestage development as a potential firsttomarket therapy for the chronic rare connective tissue disorder epidermolysis bullosa eb it is also leveraging its chaperoneadvanced replacement therapy chart platform technologies to develop ert products for pompe disease fabry disease and potentially other lysosomal storage disorders lsds the company is also investigating preclinical and discovery programs in other rare and devastating diseases including cyclindependent kinaselike  cdkl deficiency more from reuters » officers and directors john f crowley jd chairman of the board chief executive officer age  bio  compensation   reuters bradley l campbell president chief operating officer age  bio  compensation   reuters william d baird iii chief financial officer age  bio  compensation   reuters daphne e quimi senior vice president  finance and administration corporate controller age  bio  compensation   reuters kurt j w andrews senior vice president  human resources age  bio  compensation   reuters hung viet do chief scientific officer age  bio  compensation   reuters ellen s rosenberg general counsel and corporate secretary age  bio  compensation   reuters jay a barth md chief medical officer age  bio  compensation   reuters donald j hayden jr lead independent director age  bio  compensation   reuters robert a essner independent director age  bio  compensation   reuters full list on reuters » google finance beta available in hong kong  canada  us  china  ukinformation is provided as is and solely for informational purposes not for trading purposes or advice and may be delayedto see all exchange delays please see disclaimer google  google home  blog  help  report a problem  privacy policy  terms of service microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft amicus therapeutics fold  stock predictions  price targets facebook autocomplete demo post a rating  month price target   home trending sign up log in amicus therapeutics inc fold median target price   downside positive ratings  of  analysts latest  robert w baird  outperform     view all analyst ratings for fold » facebook autocomplete demo post a rating  month price target   home trending sign up log in analyst ranking   name measured ratings sucess rate avg return  mizuho      credit suisse      jefferies      cantor fitzgerald      bank of america merrill lynch      jmp securities      goldman sachs      raymond james      fbr capital markets      william blair     flashratings  contact us facebook autocomplete demo post a rating  month price target   trending sign up log in contact flashratings your emotional state excited confused worried upset panicked angry flashratings  about us facebook autocomplete demo post a rating  month price target   trending sign up log in flashratings  all research for my stocks the most comprehensive equity research coverage available online never miss a single piece of research upgrade downgrade or target price change by any analyst firm on any stock equity research by professional analysts  especially their rationales more than their forecasts  contains far more interesting and important information about the actual fundamentals of the traded companies than can be gathered from conventional news reports our mission is to unlock access to valuable research on stocks for all retail investors professionals institutions take advantage of our costeffective subscriptions to have flashratingss comprehensive realtime feed delivered into your intranet and trading floor platforms institutional subscriptions websites become a content licensing partner and display flashratingss popular news feed on your website content licensing advertisers advertise with us and have flashratings readers with attractive demographics take advantage of your products advertising flashratings  privacy facebook autocomplete demo post a rating  month price target   trending sign up log in privacy flashratings takes the privacy of its users seriously we are committed to safeguarding the privacy of our users while providing a personalised and valuable service this privacy policy statement explains the data processing practices of flashratingscom if you have any requests concerning your personal information or any queries with regard to these practices please contact us here  flashratings collects personal information when you register or when you provide such information voluntarily  we use cookies and other technologies to find out how you use flashratings  flashratings accesses information automatically when you visit our site this information includes url ipaddress browsertype language as well as date and time of your visit  we dont pass on personal information to any third party beyond other flashratings users as specified above without your explicit approval  only summarized depersonalized information is provided to third parties  personal information is used for providing services requested by the user including services with personalized content  additionally we use your personal information for internal research in order to improve your online experience as well as our technologies and services terms of use by using this website you agree to the following terms of use the content on this site including news quotes data and other information is provided by flashratings inc and its third party content providers for your personal information only and is not intended for trading purposes content on this site is not appropriate for the purposes of making a decision to carry out a transaction or trade nor does it provide any form of advice investment tax legal amounting to investment advice or make any recommendations regarding particular financial instruments investments or products neither flashratings inc nor its third party content providers shall be liable for any errors inaccuracies or delays in content or for any actions taken in reliance thereon flashratings inc expressly disclaims all warranties expressed or implied as to the accuracy of any the content provided or as to the fitness of the information for any purpose although flashratings inc makes reasonable efforts to obtain reliable content from third parties flashratings inc does not guarantee the accuracy of or endorse the views or opinions given by any third party content provider this site may point to other internet sites that may be of interest to you however flashratings inc does not endorse or take responsibility for the content on such other sites amicus therapeutics advancing therapies to treat rare diseases a rare opportunity to join a team that is making a difference in the lives of patients together we can achieve more join the amicus team a rare portfolio of programs development pipeline fabry disease program epidermolysis bullosa eb program pompe disease program preclinical programs previous next july   amicus therapeutics announces closing of underwritten offering of common stock and full exercise of option to purchase additional shares july   amicus therapeutics announces public offering of common stock july   us fda confirms amicus therapeutics may submit new drug application for migalastat for fabry disease read all news » patient voices our programs a rare company patient voices patient advocacy at amicus general disease information patient portraits patient advisory boards resources community support our programs development pipeline fabry disease program epidermolysis bullosa eb program pompe disease program preclinical programs a rare company overview welcome from chairman  ceo leadership amicus belief statement careers our locations contact us patient stories patient advocacy x bing places for business bing places for business sign in using your microsoft account work account google account facebook account dont have an account create one